Introduction {#s1}
============

Chronic lung diseases present tremendous health burdens attributed to dysfunctional alveolar repair ([@bib4]; [@bib27]; [@bib43]). Lung adenocarcinoma (LUAD), the leading cancer killer worldwide, is mainly caused by chemical carcinogens of tobacco smoke that induce mutations of the Kirsten rat sarcoma viral oncogene homologue (*KRAS*) in yet unidentified pulmonary cells ([@bib48]; [@bib13]; [@bib18]; [@bib5]; [@bib6]). The discovery of the cellular lineages and the transcriptional programs that underlie lung regeneration and carcinogenesis is extremely important, since epithelial developmental pathways are intimately related with oncogenic signaling to jointly regulate stemness and drug resistance ([@bib3]; [@bib42]). To this end, lineage-specific genes encoding epithelial proteins that support the physiological functions of the lungs were recently shown to suffer non-coding insertions and deletions in LUAD, lending further support to the longstanding notion that epithelial cells that express lung-restricted proteins are the cellular sources of LUAD ([@bib20]).

However, these cells of origin of LUAD remain only partially charted. Previous pulmonary lineage tracing studies that utilized noxious insults and ectopic expression of oncogenes in the respiratory epithelium incriminated both airway and alveolar cells as progenitors of newly formed alveoli and/or LUAD in adult mice ([@bib58]; [@bib23]; [@bib8]; [@bib55]; [@bib46]; [@bib28]; [@bib11]). To this end, airway epithelial cells (AEC) line the bronchi and include ciliated, basal, goblet, and Clara or club cells; alveolar type II cells (ATII) and alveolar macrophages (AMΦ) are distributed across the distal lung parenchyma; and bronchoalveolar stem cells (BASC) with dual AEC/ATII properties are located at the bronchoalveolar junctions. Established markers currently used to label these pulmonary lineages include acetylated tubulin (TUBA1A) for ciliated cells, keratin 5 (KRT5) for basal cells, forkhead box J1 (FOXJ1) for goblet cells, Clara cell secretory protein (CCSP) for club cells, surfactant protein C (SFTPC) and lysozyme 2 (LYZ2) for ATII cells, and LYZ2 for AMΦ, are summarized in [Figure 1A](#fig1){ref-type="fig"} and [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}, and are extensively studied in [@bib11] and [@bib49]. However, existing mouse models for lineage tracing feature incomplete and/or promiscuous lung cell labeling, that is cellular markings fail to identify all cells of a target lineage (false negative marking) or wrongfully identify other cells outside of the target lineage (false positive marking) ([@bib58]; [@bib23]; [@bib8]; [@bib55]; [@bib46]; [@bib28]; [@bib11]). In addition, all studies that attempted to address the cellular origins of LUAD to date employed overexpression of oncogenes such as *KRAS*^G12D^ in the lungs, to conclude that ATII cells or BASC are the most probable culprits of the disease ([@bib23]; [@bib8]; [@bib55]; [@bib46]; [@bib28]; [@bib11]). However, it was recently shown that oncogenic *KRAS*^G12D^-driven mouse lung tumors do not imitate the mutational landscape of human LUAD as closely as tobacco carcinogen-induced LUAD do ([@bib5]; [@bib6]; [@bib54]).

![Airway cells in urethane-induced lung tumors.\
(**A**) Cartoon of the different lung epithelial lineages, their distribution in the airways (club, goblet, ciliated, and basal cells) and the alveoli (alveolar type I and II cells), their permanent fluorescent genetic labeling in the reporter mice used in this study (green color), and the protein markers used for their identification. See also [Figure 1---figure supplements 1](#fig1s1){ref-type="fig"}--[5](#fig1s5){ref-type="fig"}. (**B**) Lung sections from naïve 6-week-old GFP;CCSP.CRE mice (*n* = 22), in which all airway cells bear permanent genetic GFP+ (green arrows) and all other cells TOMATO+ (red arrows) labels, counterstained with nuclear Hoechst33258 dye (top) or immunostained for the club cell marker CCSP and the alveolar type II cell marker SFTPC (bottom). a, alveoli; b, bronchi; v, vein. See also [Figure 1---figure supplements 6](#fig1s6){ref-type="fig"}--[8](#fig1s8){ref-type="fig"}. (**C**) Proliferating cell nuclear antigen (PCNA; brown) and hematoxylin (blue)-stained (top) and CCSP (green) and Hoechst33258 (blue)-stained (bottom) lung tumor sections of urethane-treated C57BL/6 mice six months post-treatment (*n* = 5/group), depicting endobronchial lung adenocarcinomas (white arrows). See also [Figure 1---figure supplements 9](#fig1s9){ref-type="fig"}--[11](#fig1s11){ref-type="fig"}. (**D**) Lung sections of GFP;CCSP.CRE mice (*n* = 10) at six months post-urethane treatment bearing hyperplasias and tumors (dashed outlines, top), and immunostained for the club cell marker CCSP (bottom left) and the alveolar type II cell marker SFTPC (bottom right). Note the GFP-labeled lesions of airway origin that have lost CCSP and have acquired SFTPC immunoreactivity. See also [Figure 1---figure supplements 12](#fig1s12){ref-type="fig"}--[19](#fig1s19){ref-type="fig"}. CCSP, Clara cell secretory protein; TUBA1A, acetylated α-tubulin; SFTPC, surfactant protein C; LYZ2, lysozyme 2; FOXJ1, forkhead box J1; KRT5, keratin 5.](elife-45571-fig1){#fig1}

Here we aimed at identifying the cell lineage(s) that give rise to human-relevant tobacco carcinogen-triggered LUAD in mice and that regenerate adult murine alveoli after injury. For this, we combined mouse models of genetic labeling and ablation of airway and alveolar epithelial cells with noxious and tumorigenic insults to the adult lung. To achieve this, we adapted multi-hit chemical carcinogen exposure protocols to the murine C57BL/6 strain that is resistant to chemical tumor induction ([@bib33]; [@bib29]; [@bib44]), and corroborated the findings with the FVB strain that is susceptible to single-hit carcinogenesis ([@bib54]; [@bib44]; [@bib53]). We show that aging, toxic, and carcinogen insults to the adult mouse lung cause expansion of airway-marked cells to the alveolar parenchyma, where they express the alveolar marker SFTPC and facilitate alveolar repair and carcinogenesis. In addition, we report how airway cells preferentially sustain chemical-induced *KRAS* mutations leading to LUAD that are spatially linked with neighboring bronchi. Moreover, genetic ablation of airway cells is shown to hinder alveolar maintenance and carcinogenesis in mice, indicating a central role for these cells in alveolar regeneration and LUAD triggered in response to environmental challenges.

Results {#s2}
=======

Accurate genetic labeling of the airway lineage {#s2-1}
-----------------------------------------------

To evaluate the contribution of different epithelial lung cell lineages to chemical-induced LUAD, we crossed a CRE-reporter strain that switches somatic cells from membranous tdTomato (mT; hereafter TOMATO) to membranous GFP (mG; hereafter GFP) fluorescence upon CRE-mediated recombination (mT/mG; hereafter TOMATO mice) ([@bib34]) to six different CRE-driver strains on the C57BL/6 background ([@bib11]; [@bib38]; [@bib39]; [@bib17]; [@bib37]; [@bib50]). This permitted the permanent genetic GFP*-*labeling of different lung cell lineages (mouse strains are listed in [Figure 1A](#fig1){ref-type="fig"} and [Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}, and in Materials and methods and in Appendix 1). Double heterozygote offspring at six postnatal weeks (i.e., after mouse lung development is complete \[[@bib58]; [@bib11]\]) were examined for GFP*-*labeling (results are shown in [Figure 1A](#fig1){ref-type="fig"}, [Figure 1---figure supplements 3](#fig1s3){ref-type="fig"} and [4](#fig1s4){ref-type="fig"}, and in [Figure 1---figure supplement 4---source data 1](#fig1s4sdata1){ref-type="supplementary-material"}). This approach labeled permanently all AEC of GFP;CCSP.CRE mice, some AEC and all ATII of GFP;SFTPC.CRE mice, some ATII and all AMΦ of GFP;LYZ2.CRE mice, and various other cells in the remaining intercrosses ([Figure 1A](#fig1){ref-type="fig"}, [Figure 1---figure supplements 3](#fig1s3){ref-type="fig"}--[5](#fig1s5){ref-type="fig"}, and [Figure 1---figure supplement 5---source data 1](#fig1s5sdata1){ref-type="supplementary-material"}). Co-localization of GFP*-*labeling with lineage protein markers (listed in [Figure 1A](#fig1){ref-type="fig"} and [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}) revealed that genetic GFP-labeling in GFP;CCSP.CRE mice marked all airway epithelial cells including club and ciliated cells, in GFP;SFTPC.CRE mice most airway and all alveolar epithelial type II cells, and in GFP;LYZ2.CRE mice some alveolar epithelial type II cells and all alveolar macrophages ([Figure 1B](#fig1){ref-type="fig"}, [Figure 1---figure supplements 6](#fig1s6){ref-type="fig"}--[8](#fig1s8){ref-type="fig"}, [Figure 1---figure supplement 7---source data 1](#fig1s7sdata1){ref-type="supplementary-material"}, [Figure 1---figure supplement 8---source data 1](#fig1s8sdata1){ref-type="supplementary-material"}).These findings show precise airway epithelial lineage labeling in GFP;CCSP.CRE mice and non-specific airway/alveolar/myeloid lineage labeling in GFP;SFTPC.CRE and GFP;LYZ2.CRE mice.

Airway cells in chemical-induced lung adenocarcinoma {#s2-2}
----------------------------------------------------

We next triggered LUAD in GFP;CCSP.CRE, GFP;SFTPC.CRE, and GFP;LYZ2.CRE mice on the C57BL/6 background using repetitive exposures to the tobacco carcinogens urethane (ethyl carbamate, EC; stand-alone mutagen and tumor promoter) ([@bib54]; [@bib33]; [@bib44]; [@bib53]) or 3-methylcholanthrene followed by butylated hydroxytoluene (MCA/BHT; a two-hit mutagen/tumor promoter regimen) ([@bib29]) ([Figure 1C](#fig1){ref-type="fig"}, [Figure 1---figure supplements 9](#fig1s9){ref-type="fig"} and [10](#fig1s10){ref-type="fig"}, and [Figure 1---figure supplement 10---source data 1](#fig1s10sdata1){ref-type="supplementary-material"}). In both models, preneoplastic (airway epithelial hyperplasias and atypical alveolar hyperplasias) and neoplastic (adenoma and LUAD) lesions classified according to established guidelines ([@bib36]) were located both in the airways and the alveolar regions. However, established lung tumors were most frequently located near or inside the airways ([Figure 1C](#fig1){ref-type="fig"} and [Figure 1---figure supplement 11](#fig1s11){ref-type="fig"}). All hyperplasias and tumors of GFP;SFTPC.CRE and some of GFP;LYZ2.CRE mice were GFP-labeled, but this was not informative, since baseline marking of GFP;SFTPC.CRE and GFP;LYZ2.CRE mice were non-specific. Interestingly, all hyperplasias and tumors of GFP;CCSP.CRE mice contained GFP-labeled airway cells that did not express the club cell marker CCSP anymore, but had acquired expression of the alveolar epithelial markers SFTPC with or without LYZ2 ([Figure 1D](#fig1){ref-type="fig"}, [Figure 1---figure supplements 12](#fig1s12){ref-type="fig"}--[15](#fig1s15){ref-type="fig"}, and [Figure 1---figure supplement 13---source data 1](#fig1s13sdata1){ref-type="supplementary-material"}). Identical results were recapitulated using single urethane hits to GFP;CCSP.CRE, GFP;SFTPC.CRE, and GFP;LYZ2.CRE mice backcrossed \>F12 to the susceptible FVB strain, which result in human LUAD-like mutations including *Kras*^Q61R^ ([@bib54]; [@bib53]; [@bib22]) ([Figure 1D](#fig1){ref-type="fig"} and [Figure 1---figure supplements 16](#fig1s16){ref-type="fig"}--[19](#fig1s19){ref-type="fig"}). Collectively, these data support that airway cells contribute to chemical-induced LUAD, shifting from airway to alveolar marker expression during carcinogenesis.

Airway cells sustain *Kras*^Q61R^ mutations and give rise to juxtabronchial tumors {#s2-3}
----------------------------------------------------------------------------------

We next used digital droplet PCR (ddPCR) to determine the lung lineages that suffer *Kras*^Q61R^ driver mutations at early time-points after single urethane hits ([@bib54]; [@bib53]; [@bib22]). For this, GFP;CCSP.CRE and GFP;LYZ2.CRE mice backcrossed \>F12 to the susceptible FVB strain received urethane and duplexed ddPCR designed to single-copy-co-amplify *Kras* and *Rosa^mT^* was performed one and two weeks later. Interestingly, GFP-labeled cells of both mouse strains had *Kras*^Q61R^ mutations at one week post-urethane, but *Kras*^Q61R^ mutations selectively persisted in GFP-labeled airway cells in the lungs of GFP;CCSP.CRE mice at two weeks ([Figure 2A](#fig2){ref-type="fig"}, [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}, and [Figure 2---source data 1](#fig2sdata1){ref-type="supplementary-material"}). In addition, three-dimensional reconstruction of tumor-bearing lungs of FVB mice at 6 months post-urethane using high-resolution micro-computed tomography (μCT) revealed that most lung tumors were spatially linked with the airways, in accord with pathology results ([Figure 2B and C](#fig2){ref-type="fig"}, and [Figure 2---source data 2](#fig2sdata2){ref-type="supplementary-material"}). These results support the involvement of airway cells in chemical-induced lung adenocarcinoma formation in mice.

![Airway cells sustain *Kras*^Q61R^ mutations inflicted by urethane and give rise to juxtabronchial lung adenocarcinomas.\
(**A**) DNA was extracted from the lungs of GFP;CCSP.CRE and GFP;LYZ2.CRE mice (FVB strain) one and two weeks post-urethane treatment (*n* = 5/group). Summary of duplexed digital droplet PCR (ddPCR) results using primers and probes specific for the *Rosa^mT^* and the *Kras*^WT^ sequences. Note that all cell types equally suffer initial *Kras*^Q61R^ mutations, but only GFP-labeled cells of GFP;CCSP.CRE mice (i.e. airway cells) maintain the *Kras*^Q61R^ mutation after two weeks. See also [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}. Data are shown as violin plot. *P*, overall probability, two-way ANOVA. \*\*\*: p\<0.001 compared with all other groups, Bonferroni post-tests. (**B**) Representative high-resolution micro-computed tomography (μCT) lung sections (top) and three-dimensional reconstructions (bottom) from urethane-treated FVB mice six months after treatment (*n* = 10). Note lung tumors attached to (green arrows) or contained within (blue arrows) the airways, as well as lung tumors with no obvious link to a bronchus (red arrows). (**C**) Summary of results from μCT (data from [Figure 2B](#fig2){ref-type="fig"}) and pathology (data from [Figure 1C](#fig1){ref-type="fig"}) shown as violin plot. *P*, probability, two-way ANOVA.\*, \*\*\*, and \*\*\*\*: p\<0.05, p\<0.001, and p\<0.0001, respectively, compared with airway-attached tumors, Bonferroni post-tests. Shown are also Spearman's correlation coefficient (*ρ*) and probability (**P**) for correlation of μCT and pathology results.\
10.7554/eLife.45571.031Figure 2---source data 1.Quantification of*Kras*mutant droplets in duplexed digital droplet PCR (ddPCR).\
10.7554/eLife.45571.032Figure 2---source data 2.Quantification of tumor airway link.](elife-45571-fig2){#fig2}

Alveolar dissemination of airway-labeled cells during carcinogenesis {#s2-4}
--------------------------------------------------------------------

Since airborne carcinogens act globally on the respiratory field ([@bib15]), we examined non-neoplastic alveolar areas of carcinogen-treated GFP;CCSP.CRE mice, to discover markedly increased numbers of GFP-labeled cells in the alveoli of carcinogen-treated mice compared with saline-treated or naïve controls ([Figure 3A](#fig3){ref-type="fig"}, [Figure 3---figure supplements 1](#fig3s1){ref-type="fig"} and [2](#fig3s2){ref-type="fig"}, and [Figure 3---figure supplement 2---source data 1](#fig3s2sdata1){ref-type="supplementary-material"}). Immunostaining revealed that juxtabronchial GFP-labeled cells still expressed CCSP, but lost CCSP and acquired SFTPC expression when located in alveoli and tumors ([Figure 3B](#fig3){ref-type="fig"} and [Figure 3---figure supplements 3](#fig3s3){ref-type="fig"} and [4](#fig3s4){ref-type="fig"}). The expansion of airway cells after urethane exposure was also documented using bioluminescent imaging of double heterozygote offspring of CCSP.CRE intercrosses with Luciferase-expressing (LUC) mice ([@bib41]), a strain emitting light specifically from airway epithelia ([Figure 3---figure supplement 5](#fig3s5){ref-type="fig"}, and [Figure 3---figure supplement 5---source data 2](#fig3s5sdata2){ref-type="supplementary-material"}). In addition, co-staining of human LUAD ([@bib16]) for the alveolar marker SFTPC and the airway markers CCSP and KRT5 showed co-localization of SFTPC with KRT5 but not with CCSP ([Figure 3C](#fig3){ref-type="fig"} and [Figure 3---figure supplement 6](#fig3s6){ref-type="fig"}). These results suggest that airway epithelial cells expand to alveolar regions during field cancerization by tobacco carcinogens, a process involving either direct alveolar cell recycling by airway epithelial cells or transient CCSP expression by alveolar cells during carcinogenesis. Moreover, that human and murine LUAD carry airway imprints although their location and protein expression suggests an alveolar origin ([@bib11]; [@bib1]; [@bib31]; [@bib26]; [@bib47]).

![Expansion of airway cells in the tumor-initiated lung.\
(**A**) Non-neoplastic alveolar regions from lung sections of saline-, urethane (ethyl carbamate, EC)-, and 3-methyl-1,2-dyhydrobenzo\[j\]aceanthrylene/butylated hydroxytoluene (MCA/BHT)-treated GFP;CCSP.CRE mice at six months into treatment (*n* = 8 mice/group). Note the few GFP-labeled cells of saline-treated mice and their increased numbers in carcinogen-treated mice (arrows). See also [Figure 3---figure supplements 1](#fig3s1){ref-type="fig"} and [2](#fig3s2){ref-type="fig"}. (**B**) Juxtabronchial region from lung section of urethane-treated GFP;CCSP.CRE mouse at six months into treatment (*n* = 22) stained for the alveolar type II cell marker SFTPC. Arrows and legend indicate different phenotypes of extrabronchial GFP-labeled cells. See also [Figure 3---figure supplements 3](#fig3s3){ref-type="fig"}--[5](#fig3s5){ref-type="fig"}. (**C**) Merged high-power image of SFTPC and KRT5 co-staining of human lung adenocarcinoma (*n* = 10) shows significant co-localization of the two markers in a subset of tumor cells (arrows). See also [Figure 3---figure supplement 6](#fig3s6){ref-type="fig"}. CCSP, Clara cell secretory protein; SFTPC, surfactant protein C; KRT5, keratin 5.](elife-45571-fig3){#fig3}

Airway cells in the aging and injured adult alveolus {#s2-5}
----------------------------------------------------

We next examined the kinetics of lineage-labeled cells during aging, injury, and repair. While the number of GFP-labeled cells in the alveoli of aging GFP;SFTPC.CRE and GFP;LYZ2.CRE mice was stable, GFP-labeled airway cells in the alveoli of aging GFP;CCSP.CRE mice progressively increased and expressed SFTPC protein ([Figure 4A and B](#fig4){ref-type="fig"} and [Figure 4---source data 1](#fig4sdata1){ref-type="supplementary-material"}). Bleomycin treatment, which depletes alveolar type II cells ([@bib24]), accelerated the accumulation of GFP-labeled airway cells in the alveoli and in urethane-triggered LUAD ([Figure 4C and D](#fig4){ref-type="fig"}, [Figure 4---figure supplements 1](#fig4s1){ref-type="fig"} and [2](#fig4s2){ref-type="fig"}, [Figure 4---source data 2](#fig4sdata2){ref-type="supplementary-material"}, and [Figure 4---figure supplement 2---source data 1](#fig4s2sdata1){ref-type="supplementary-material"}). GFP-labeled airway cells expressing the alveolar marker SFTPC also increased in the alveoli of GFP;CCSP.CRE mice exposed to perinatal hyperoxia that damages forming alveoli ([@bib40]), and in the alveoli of GFP;CCSP.CRE mice treated with naphthalene that kills airway epithelial cells ([@bib47]; [@bib40]), but were not identified within the airways of naphthalene-treated GFP;CCSP.CRE mice; these appeared to be repopulated by GFP-labeled airway cells that express the club cell marker CCSP ([Figure 4E--4H](#fig4){ref-type="fig"}, [Figure 4---figure supplements 3](#fig4s3){ref-type="fig"} and [4](#fig4s4){ref-type="fig"}, [Figure 4---source datas 3](#fig4sdata3){ref-type="supplementary-material"} and [4](#fig4sdata4){ref-type="supplementary-material"}, and [Figure 4---figure supplement 4---source data 2](#fig4s4sdata2){ref-type="supplementary-material"}). In line with the latter finding, no GFP-labeled alveolar cells were identified in the airways of GFP;LYZ2.CRE mice recovering from naphthalene-induced injury ([Figure 4G and H](#fig4){ref-type="fig"}). Taken together, the data indicate that airway-originated cells repopulate both the airways and the alveoli during aging and recovery from injury, while alveolar cells do not reconstitute the airways, in line with previous findings ([@bib11]; [@bib40]). The observed alveolar spread of airway-labeled cells was explained by either peripheral migration of airway cells or transient CCSP expression by regenerating alveolar cells.

![Airway cells in alveolar repair.\
(**A**) Non-neoplastic alveolar regions from lung sections of aging GFP;CCSP.CRE mice (bottom right section is also SFTPC-immunostained) show increasing numbers of alveolar GFP-labeled cells with age (arrows). Green arrows: genetically GFP-labeled, SFTPC-immunoreactive airway cells in alveolus of 15-month-old GFP;CCSP.CRE mouse. (**B**) Data summary (*n* = 5 mice/time-point) from (**A**) shown as violin plot. Color-coded boxes indicate time windows of experiments in (**C-H**). *P*, probability, one-way ANOVA. ns, \*\*\*, and \*\*\*\*: p\>0.05, p\<0.001, and p\<0.0001, respectively, for comparison with time-point zero by Bonferroni post-tests. (**C**) SFTPC-immunostained lung sections of GFP;CCSP.CRE mice show accelerated increase of alveolar GFP-labeled SFTPC-immunoreactive airway cells after bleomycin treatment (arrows). See also [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"} and [Figure 4---figure supplement 2](#fig4s2){ref-type="fig"}. (**D**) Data summary from (**C**) shown as violin plots (*n* = 4 mice/time-point). *P*, probabilities, one-way ANOVA. ns, \*, \*\*, \*\*\*, and \*\*\*\*: p\>0.05, p\<0.05, p\<0.01, p\<0.001, and p\<0.0001, respectively, for comparison with day zero by Bonferroni post-tests. (**E**) SFTPC-stained lung sections of GFP;CCSP.CRE mice at two months after perinatal exposure to 98% O~2~ show enlarged alveoli (evident by increased mean linear intercept) enriched in GFP-labeled SFTPC-immunoreactive airway cells (arrows) compared with 21% O~2~. (**F**) Data summary from (**E**) shown as violin plots (*n* = 6 mice/group). *P*, probabilities, t-test. (**G**) Lung sections (top) of GFP;CCSP.CRE mice (*n* = 5 mice/group) show enrichment of alveoli in GFP-labeled cells post-naphthalene treatment (arrows). Lung sections (bottom) of GFP;LYZ2.CRE mice (*n* = 5 mice/group) at six weeks post-naphthalene show no bronchial (**b**) GFP-labeled cells. See also [Figure 4---figure supplements 3](#fig4s3){ref-type="fig"} and [4](#fig4s4){ref-type="fig"}. (**H**) Data summary from (**G**) shown as violin plot (*n* = 5 mice/time-point). *P*, probability, two-way ANOVA. ns and \*\*\*\*: p\>0.05 and p\<0.0001, respectively, for comparison with corn oil by Bonferroni post-tests. CCSP, Clara cell secretory protein; SFTPC, surfactant protein C; LYZ2, lysozyme 2.\
10.7554/eLife.45571.047Figure 4---source data 1.Quantification of alveolar GFP+ cells in GFP;CCSP.CRE mice during aging.\
10.7554/eLife.45571.048Figure 4---source data 2.Quantification of SFTPC+ and GFP+ cells in GFP;CCSP.CRE mice after bleomycin treatment.\
10.7554/eLife.45571.049Figure 4---source data 3.Data of mean linear intercept and GFP+/SFTPC+cells in GFP;CCSP.CRE mice after hyperoxia treatment.\
10.7554/eLife.45571.050Figure 4---source data 4.Data of GFP+/SFTPC+ cells in GFP;CCSP.CRE and GFP;LYZ2.CRE mice after naphthalene treatment.](elife-45571-fig4){#fig4}

Airway cells maintain alveoli and foster tumors {#s2-6}
-----------------------------------------------

To further examine the role of airway and alveolar cells in alveolar homeostasis and lung carcinogenesis, we ablated them by crossing CCSP.CRE, SFTPC.CRE, and LYZ2.CRE mice to mice expressing Diphtheria toxin in somatic cells upon CRE-mediated recombination (DTA mice) ([@bib52]). Triple transgenic GFP;DRIVER.CRE;DTA intercrosses were also generated to evaluate ablation efficiency. As expected, SFTPC.CRE;DTA and GFP;SFTPC.CRE;DTA mice were fetal lethal (no double or triple heterozygote offspring was obtained by *n* \> 3 intercrosses,\>10 litters, and \>60 off-springs for each genotype; p\<0.0001, Fischer's exact test). However, all other ablated mice survived till adulthood. Airway epithelial ablation was complete in GFP;CCSP.CRE;DTA mice, while some GFP-labeled alveolar macrophages persisted in GFP;LYZ2.CRE;DTA mice, presumably freshly recruited monocytes initiating LYZ2 expression. Immunostaining revealed that the denuded airway epithelium of 12-week-old GFP;CCSP.CRE;DTA mice contained few flat CCSP+SFTPC+LYZ2+ immunoreactive cells, while the apparently intact alveolar spaces of GFP;LYZ2.CRE;DTA mice harbored only some CCSP-SFTPC-LYZ2+immunoreactive alveolar macrophages ([Figure 5A](#fig5){ref-type="fig"}, [Figure 5---figure supplements 1](#fig5s1){ref-type="fig"} and [2](#fig5s2){ref-type="fig"}, and [Figure 5---figure supplement 2---source data 1](#fig5s2sdata1){ref-type="supplementary-material"}). Remarkably, morphometric and functional analyses of 12-week-old DTA control, CCSP.CRE;DTA, and LYZ2.CRE;DTA mice showed that LYZ2.CRE;DTA mice displayed normal airway caliper and mean linear intercept (measures of airway and alveolar structure), normal number of CD45+ CD11b+ myeloid cells in bronchoalveolar lavage (BAL; measure of airspace inflammation), and normal airways resistance and static compliance (measures of airway and alveolar function) compared with DTA controls. However, CCSP.CRE;DTA mice displayed widened airway and alveolar dimensions with inflammatory interalveolar septal destruction evident by increased mean linear intercept, CD45+ CD11b+ cells in BAL, and static compliance ([Figure 5B and C](#fig5){ref-type="fig"} and [Figure 5---source data 1](#fig5sdata1){ref-type="supplementary-material"}), mimicking human chronic obstructive pulmonary disease ([@bib4]). Finally, we exposed control and ablated mice to ten consecutive weekly urethane exposures. All mice survived six months into carcinogen treatment, and CCSP.CRE;DTA and LYZ2.CRE;DTA mice were equally protected from LUAD development compared with controls ([Figure 5D and E](#fig5){ref-type="fig"}, and [Figure 5---source data 2](#fig5sdata2){ref-type="supplementary-material"}). Taken together, these results show that the CCSP+ airway lineage maintains postnatal alveolar structure and function, and, together with the LYZ2+ alveolar lineage, are required for lung adenocarcinoma development.

![Airway cell-ablated mice display alveolar destruction and are protected from carcinogenesis.\
(**A**) Lineage marker-immunostained lung sections of 12-week-old GFP;CCSP.CRE;DTA and GFP;LYZ2.CRE;DTA mice (*n* = 6/group) show increased bronchial and alveolar size and flat CCSP+ SFTPC+ LYZ2+ cells in the airways of GFP;CCSP.CRE;DTA mice (green arrows), and CCSP-SFTPC-LYZ2+ alveolar macrophages in the airspaces of GFP;LYZ2.CRE;DTA mice (blue arrows). See also [Figure 5---figure supplements 1](#fig5s1){ref-type="fig"} and [2](#fig5s2){ref-type="fig"}. (**B**) Hematoxylin and eosin-stained lung sections (*n* = 6/group) from 12-week-old DTA (controls), CCSP.CRE;DTA (airway epithelial suicide model), and LYZ2.CRE;DTA (alveolar epithelial suicide model) mice. (**C**) Data summaries of mean linear intercept, bronchoalveolar lavage (BAL) myeloid cells, pressure-volume curves, airway resistance, and static compliance (*n* = 6--10/group) from 12-week-old DTA, CCSP.CRE;DTA, and LYZ2.CRE;DTA mice shown as violin plots. *P*, probabilities, one-way ANOVA. ns, \*\*, and \*\*\*: p\>0.05, p\<0.01, and p\<0.001, respectively, for the indicated comparisons, Bonferroni post-tests. (**D**) Lung photographs of control, CCSP.CRE;DTA, and LYZ2.CRE;DTA mice at six months into treatment with urethane started at six weeks of age. (**E**) Incidence table and data summaries of lung tumors from (**D**) (violin plots; *n* is given in table). *P*, probabilities, χ^2^-test (table) and one-way ANOVA (graphs). ns, \*, \*\*, and \*\*\*: p\>0.05, p\<0.05, p\<0.01, and p\<0.001, respectively, for the indicated comparisons, Fischer's exact tests (table) or Bonferroni post-tests (graphs). a, alveoli; b, bronchi; ps, pleural space; v, vessel. CCSP, Clara cell secretory protein; SFTPC, surfactant protein C; LYZ2, lysozyme 2.\
10.7554/eLife.45571.056Figure 5---source data 1.Quantifications of data shown in [Figure 5C](#fig5){ref-type="fig"}.\
10.7554/eLife.45571.057Figure 5---source data 2.Quantifications of data shown in [Figure 5D and E](#fig5){ref-type="fig"}.](elife-45571-fig5){#fig5}

Airway epithelial signatures in experimental and human lung adenocarcinoma {#s2-7}
--------------------------------------------------------------------------

We subsequently examined the transcriptomes of cell lines isolated from urethane-induced LUAD ([@bib22]) and of murine lungs with those of murine AEC isolated from tracheal explants, of murine ATII cells ([@bib14]), and of murine bone-marrow-derived macrophages (BMDM). The AEC transcriptome was specifically enriched in LUAD cells compared with whole lungs ([Figure 6A and B](#fig6){ref-type="fig"}, [Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}, and [Figure 6---source data 1](#fig6sdata1){ref-type="supplementary-material"}). LUAD cell lines lost expression of epithelial markers compared with their native lungs, but displayed up-regulated expression of LUAD markers (i.e., *Krt18* and *Krt20*), of epidermal growth factor receptor ligands (*Areg* and *Ereg*), and of the *Myc* oncogene ([Figure 6---figure supplements 2](#fig6s2){ref-type="fig"}--[4](#fig6s4){ref-type="fig"}, and [Figure 6---figure supplement 2---source data 1](#fig6s2sdata1){ref-type="supplementary-material"}). Similar analyses of the transcriptomes of human LUAD and corresponding healthy lungs ([@bib21]), and of primary human AEC, ATII, and AMΦ ([@bib9]; [@bib10]; [@bib25]) also disclosed that the AEC transcriptome was significantly enriched in LUAD compared with healthy lungs ([Figure 6C and D](#fig6){ref-type="fig"} and [Figure 6---source data 2](#fig6sdata2){ref-type="supplementary-material"}). Gene set enrichment analyses (GSEA) showed that the mouse AEC transcriptome predominated over ATII/BMDM transcriptomes in LUAD cells ([Figure 6E](#fig6){ref-type="fig"}, [Figure 6---figure supplement 5](#fig6s5){ref-type="fig"}, and [Figure 6---source data 3](#fig6sdata3){ref-type="supplementary-material"}). In addition, the human AEC transcriptome was enriched equally with ATII/AMΦ transcriptomes in human LUAD compared with healthy lungs ([Figure 6F](#fig6){ref-type="fig"}, [Figure 6---figure supplement 6](#fig6s6){ref-type="fig"}, and [Figure 6---source data 4](#fig6sdata4){ref-type="supplementary-material"}). These results showed the presence of an anticipated alveolar and an unexpected airway epithelial transcriptomic signature in tobacco carcinogen-induced LUAD of mice and men. The more pronounced results in mice were plausible by the early nature of the human surgical specimens examined compared with our murine cell lines that present advanced metastatic tumor cells.

![Airway and alveolar signatures in murine and human lung adenocarcinoma (LUAD).\
(**A, B**) RNA of mouse urethane-induced LUAD cell lines, lungs obtained pre- and one week post-urethane treatment, airway epithelial cells (AEC), alveolar type II cells (ATII), and bone marrow-derived macrophages (BMDM) was examined by Affymetrix Mouse Gene ST2.0 microarrays (*n* = 4/group). (**A**) Heat map of genes significantly differentially expressed (overall ANOVA and FDR p\<10^−6^) shows accurate hierarchical clustering. (**B**) Expression of the 30 top-represented transcripts of AEC, ATII, and BMDM in lungs and LUAD cells. See also [Figure 6---figure supplements 1](#fig6s1){ref-type="fig"}--[4](#fig6s4){ref-type="fig"}. (**C, D**) RNA of human LUAD (*n* = 40), never-smoker lung tissue (*n* = 30), primary AEC (*n* = 5), primary ATII (*n* = 4), and alveolar macrophages (AMΦ; *n* = 9) was analyzed by Affymetrix Human Gene ST1.0 microarrays. (**C**) Heat map of genes significantly differentially expressed (*Δ*GE \> 5 fold) between LUAD and lung (ANOVA and FDR p\<10^−3^) shows accurate hierarchical clustering. (**D**) Mean expression levels of the 30 top-represented transcripts of human AEC, ATII, and AMΦ in lungs and LUAD. (**E, F**) Gene set enrichment analyses, including normalized enrichment scores (NES), of mouse (**E**) and human (**F**) AEC, ATII, and BMDM/AMΦ signatures (defined as the top 1% expressed genes overall or exclusive to the cell type; *n* = 2) in mouse and human LUAD transcriptomes shows significant enrichment of the AEC (but not the ATII and BMDM/AMΦ) signature compared with lung (nominal p\<0.0001 for all, family-wise error rates FWER \<0.01). Gene symbols indicate the top three lagging genes from each signature and shows loss of *Scgb1a1* (encoding CCSP) by LUAD. See also [Figure 6---figure supplements 5](#fig6s5){ref-type="fig"} and [6](#fig6s6){ref-type="fig"}. Data are given as violin plots. *P*, two-way ANOVA probabilities. ns, \*, \*\*, and \*\*\*: p\>0.05, p\<0.05, p\<0.01, and p\<0.001 for the indicated comparisons by Bonferroni post-tests. ANOVA, analysis of variance; FDR, false discovery rate.\
10.7554/eLife.45571.066Figure 6---source data 1.Cross-examination of signature genes of murine AEC, ATII cells, BMDM, LUAD cells and lungs.\
10.7554/eLife.45571.067Figure 6---source data 2.Cross-examination of signature genes of human AEC, ATII cells, BMDM, LUAD cells and lungs.\
10.7554/eLife.45571.068Figure 6---source data 3.Quantification of gene set enrichment analyses data shown in [Figure 6E](#fig6){ref-type="fig"}.\
10.7554/eLife.45571.069Figure 6---source data 4.Quantification of gene set enrichment analyses data shown in [Figure 6F](#fig6){ref-type="fig"}.](elife-45571-fig6){#fig6}

Discussion {#s3}
==========

We characterized the dynamics of respiratory epithelial cells in the postnatal mouse lung during aging and after challenge with noxious and carcinogenic insults. The contributions of airway cells to chemical-induced lung adenocarcinoma are described for the first time ([Figure 7A](#fig7){ref-type="fig"}). Although the peripheral location and molecular phenotype of murine and human lung adenocarcinoma (i.e., the expression of the alveolar epithelial marker SFTPC) suggest an alveolar origin, we show here that both airway and alveolar cells are found in environmental-induced lung adenocarcinoma and that, in fact, airway cells may play a more prominent role during the initial steps of carcinogenesis. Furthermore, airway cells are implicated in postnatal alveolar maintenance during aging and recovery from injury. Our analyses facilitate insights into the dynamics of epithelial lineages in the postnatal lung ([Figure 7B](#fig7){ref-type="fig"}) and indicate that airway cells are essential for the sustained structural and functional integrity of adult alveoli. Finally, mouse and human lung adenocarcinomas are shown to bare transcriptome markings of highly enriched airway signatures, rendering our findings plausible in both experimental and human lung adenocarcinoma.

![Proposed role of airway-marked cells in murine lung maintenance and adenocarcinoma.\
(**A**) Our evidence supports the existence of distinct developmental ancestries for airway epithelial (AEC) and alveolar type II (ATII) cells, notwithstanding their common descent from an early (possibly *Sftpc*+) lung epithelial progenitor. The developmental airway lineage (*Scgb1a1+ Sftpc*±; green) gives rise to all types of airway cells, including club, ciliated, goblet, basal, and other cells, while the developmental ATII lineage (*Sftpc+ Lyz2*±; red) gives rise to ATII cells before birth. These lineages appear to be segregated in the growing unaffected lung of the mouse till the age of six weeks, which roughly corresponds to a human age of six years, where cellular proliferation in the human lungs ceases. Thereafter, and likely due to the continuous exposure of the lungs to inhaled noxious agents, gradual expansion of *Scgb1a1+ Sftpc*± marked cells ensues. Upon lung injury, this process is accelerated. Similarly, during carcinogenesis caused by chemical tobacco smoke carcinogens, *Scgb1a1+ Sftpc*± marked cells expand and are ubiquitously present in peripheral lung adenocarcinomas. (**B**) Proposed neonatal proportions and postnatal dynamics of pulmonary epithelial cells during adulthood. Estimated proportions of lineage-marked cells at birth, based on flow cytometry and co-localization of proteinaceous and genetic cell marking. Lung lineages appear to be segregated in the growing lung till the age of full lung development (six weeks in mice and 6--8 years in humans) or till lung injury ensues. Schematic of proposed postnatal redistribution of marked cells in the adult lung. Upon injury, during multi-stage field carcinogenesis, or even during unchallenged aging, *Scgb1a1*+ marked cells appear in the distal alveolar regions, thereby maintaining lung structure and function. Bubble size indicates relative marked cell abundance. CCSP, Clara cell secretory protein; FOXJ1, forkhead box J1; KRT5, keratin 5; LYZ2, lysozyme 2; SFTPC, surfactant protein C; TUB1A1, acetylated α-tubulin.](elife-45571-fig7){#fig7}

This study addresses the cellular and molecular signatures of chemical-induced lung adenocarcinoma. Lung tumors induced in two different mouse strains by two different chemical regimens contained in tobacco smoke are shown to contain airway epithelial markings. This is important because human lung adenocarcinoma is inflicted by chronic exposure to tobacco smoke and other environmental exposures ([@bib18]; [@bib5]; [@bib6]; [@bib54]; [@bib33]; [@bib29]; [@bib2]; [@bib7]). As such, the mutation profile of the human disease is more closely paralleled by chemical-induced murine lung tumors compared with lung cancers triggered by transgenic expression of *Kras*^G12C^ or *Kras*^G12D^ in the respiratory epithelium ([@bib54]). Although the latter transgenic tumors have been extensively studied ([@bib23]; [@bib8]; [@bib55]; [@bib46]; [@bib28]; [@bib11]), chemical-induced lung adenocarcinomas have not been investigated. In all mouse models we studied, all tumors contained the airway genetic marking, in contrast with the LYZ2 alveolar genetic marking which was dispensable for lung adenocarcinoma development. Our observations support the multi-stage field concept of chemical carcinogenesis ([@bib15]), according to which tumor-initiated cells undergo multiple steps of genomic evolution and phenotypic appearance that include an obligatory airway-like stage. In fact, the prevalence of a different *Kras* mutation in urethane-induced tumors (*Kras*^Q61R^) compared to *KRAS*^G12C/D^ mutations in the transgenic mouse models has led to the suggestion that chemical carcinogens introduce *KRAS* mutations in a different population of tumor-initiating cells than mouse models of genetic *KRAS* activation ([@bib54]). Our findings of airway epithelial cells being more sensitive than alveolar type II cells to *Kras*^Q61R^ mutations during the initial steps of urethane-induced carcinogenesis further supports this notion and render airway cells an attractive novel target for premalignancy.

The consistent finding of CCSP genetic markings (indicative of airway epithelial origin) together with SFTPC and LYZ2 protein expression (indicative of alveolar epithelial phenotype) in chemical-triggered lung adenocarcinomas and their precursor lesions implies three different scenarios for lung adenocarcinoma formation: i) airway epithelial cells colonize the distal lung during carcinogenesis thereby activating obligate (SFTPC+) and dispensable (LYZ2+) alveolar transcriptomes; ii) alveolar cells transit through an obligate CCSP+ with or without a dispensable LYZ2+ stage during the process; or iii) lung adenocarcinoma arises from multipotent progenitors that express multiple epithelial markers, such as those found during pulmonary embryogenesis, in human lung adenocarcinoma, and in other chronic lung diseases ([@bib11]; [@bib14]; [@bib56]). However, in our view, the propensity of airway cells to survive *KRAS* mutations during early carcinogenesis, the close airway-proximity of lung tumors revealed by μCT and histology, as well as the fact that CCSP-labeled cells did not express the CCSP marker anymore, support a bronchial origin of these tumors. This view is in line with recent evidence for tobacco smoke-induced epigenetic changes that sensitize human airway epithelial cells to a single *KRAS* mutation ([@bib51]). Along these lines, the split genetic markings of chemical-induced lung adenocarcinomas of GFP;LYZ2.CRE mice indicates that LYZ2-labeled alveolar cells are dispensable for environmental lung adenocarcinoma, as opposed to what was previously shown for genetically-triggered lung adenocarcinoma ([@bib11]).

Our approach focused on the integral assessment of changes in lung epithelial kinetics and transcriptome signatures during aging, injury, and carcinogenesis. The perpetual cell labeling approach we adopted was preferred over pulsed lineage tracing models because of the unprecedented accuracy of our CCSP.CRE strain in exclusively and completely labeling airway epithelial cells at the conclusion of development, allowing tracking of subsequent changes in adulthood. The identification of transcriptional programs that are activated during lung repair and carcinogenesis are of great importance for lung biology and are likely to lead to therapeutic innovations ([@bib35]). To this end, insertions and deletions in lineage-restricted genes were recently shown to occur in human lung adenocarcinoma ([@bib20]). Moreover, integrin β~3~ and TANK-binding kinase one partner with oncogenic *KRAS* signaling to mediate cancer stemness and drug resistance ([@bib3]; [@bib42]). Along these lines, our findings of the involvement of airway epithelial cells in lung maintenance, repair, and carcinogenesis imply that at least some of these cells present lung stem cells with regenerative and malignant potential and thus marked therapeutic targets. This was evident in our hands by the facts that airway epithelial cells could maintain adult injured alveoli and sustain *KRAS* mutations induced by urethane.

In conclusion, airway cells contribute to alveolar maintenance and lung carcinogenesis in response to environmental challenges. Since defective epithelial repair underlies the pathogenesis of chronic lung diseases and since abundantly transcribed genes are central to the mutational processes that cause cancer, this finding is of potential therapeutic importance for chronic pulmonary diseases and lung cancer.

Materials and methods {#s4}
=====================

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type\                                Designation                                                         Source or reference                                                                                                                                                                                                 Identifiers                                                                                Additional\
  (species) or resource                                                                                                                                                                                                                                                                                                                                                                                                           information
  -------------------------------------------- ------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------ -----------------------------------------------------------------------------------------------------------------------------------
  Strain, strain background (*Mus musculus*)   C57BL/6                                                             Jackson Laboratory                                                                                                                                                                                                  Stock \#: 000664; RRID:[IMSR_JAX:000664](https://scicrunch.org/resolver/IMSR_JAX:000664)   

  Strain, strain background (*M. musculus*)    FVB                                                                 Jackson Laboratory                                                                                                                                                                                                  Stock \#: 001800; RRID:[IMSR_JAX:001800](https://scicrunch.org/resolver/IMSR_JAX:001800)   

  Genetic reagent (*M. musculus*)              TOMATO                                                              Jackson Laboratory                                                                                                                                                                                                  Stock \#: 007676; RRID:[IMSR_JAX:007676](https://scicrunch.org/resolver/IMSR_JAX:007676)   [@bib34]

  Genetic reagent (*M. musculus*)              LUC                                                                 Jackson Laboratory                                                                                                                                                                                                  Stock \#: 005125; RRID:[IMSR_JAX:005125](https://scicrunch.org/resolver/IMSR_JAX:005125)   [@bib41]

  Genetic reagent (*M. musculus*)              DTA                                                                 Jackson Laboratory                                                                                                                                                                                                  Stock \#: 009669; RRID:[IMSR_JAX:009669](https://scicrunch.org/resolver/IMSR_JAX:009669)   [@bib52]

  Genetic reagent (*M. musculus*)              LYZ2.Cre                                                            Jackson Laboratory                                                                                                                                                                                                  Stock \#: 004781; RRID:[IMSR_JAX:004781](https://scicrunch.org/resolver/IMSR_JAX:004781)   PMID: [10621974](https://www.ncbi.nlm.nih.gov/pubmed/10621974)

  Genetic reagent (*M. musculus*)              SOX2.Cre                                                            Jackson Laboratory                                                                                                                                                                                                  Stock \#: 008454; RRID:[IMSR_JAX:008454](https://scicrunch.org/resolver/IMSR_JAX:008454)   [@bib17]

  Genetic reagent (*M. musculus*)              VAV.Cre                                                             Jackson Laboratory                                                                                                                                                                                                  Stock \#: 008610; RRID:[IMSR_JAX:008610](https://scicrunch.org/resolver/IMSR_JAX:008610)   [@bib37]

  Genetic reagent (*M. musculus*)              NES.Cre                                                             Jackson Laboratory                                                                                                                                                                                                  Stock \#: 003771; RRID:[IMSR_JAX:003771](https://scicrunch.org/resolver/IMSR_JAX:003771)   [@bib50]

  Genetic reagent (*M. musculus*)              CCSP.Cre                                                            European Mouse Mutant Archive                                                                                                                                                                                       Stock \#: EM:04965; RRID:[IMSR_M231009](https://scicrunch.org/resolver/IMSR_M231009)       [@bib38]

  Genetic reagent (*M. musculus*)              SFTPC.Cre                                                           Mouse Genome Informatics                                                                                                                                                                                            RRID:[MGI:3574949](https://scicrunch.org/resolver/MGI:3574949)                             [@bib39]

  Cell line (*M. musculus*)                    LUAD cells                                                          PMID: [30828726](https://www.ncbi.nlm.nih.gov/pubmed/30828726)                                                                                                                                                                                                                                                 Derived from urethane models

  Biological sample (*Homo sapiens*)           Lung adenocarcinomas                                                [@bib16]                                                                                                                                                                                                                                                                                                       Archival samples of patients with LUAD

  Antibody                                     rabbit poyclonal anti-PCNA                                          Abcam                                                                                                                                                                                                               Cat. \#: ab2426; RRID:[AB_303062](https://scicrunch.org/resolver/AB_303062)                IHC (1:3000)

  Antibody                                     rabbit monoclonal anti-LYZ2                                         Abcam                                                                                                                                                                                                               Cat. \#: ab108508; RRID:[AB_10861277](https://scicrunch.org/resolver/AB_10861277)          IF (1:50)

  Antibody                                     rabbit polyclonal anti-KRT5                                         Abcam                                                                                                                                                                                                               Cat. \#: ab53121; RRID:[AB_869889](https://scicrunch.org/resolver/AB_869889)               IF (1:200)

  Antibody                                     rabbit polyclonal anti-SFTPC                                        Santa Cruz Biotechnology                                                                                                                                                                                            Cat. \#: sc-13979; RRID:[AB_2185502](https://scicrunch.org/resolver/AB_2185502)            IF (1:200)

  Antibody                                     rabbit polyclonal anti-CCSP                                         Santa Cruz Biotechnology                                                                                                                                                                                            Cat. \#: sc-25555; RRID:[AB_2269914](https://scicrunch.org/resolver/AB_2269914)            IF (1:200)

  Antibody                                     goat polyclonal anti-CCSP                                           Santa Cruz Biotechnology                                                                                                                                                                                            Cat. \#: sc-9772; RRID:[AB_2238819](https://scicrunch.org/resolver/AB_2238819)             IF (1:1000)

  Antibody                                     mouse monoclonal anti-acetylated α-tubulin                          Sigma-Aldrich                                                                                                                                                                                                       Cat. \#: T7451; RRID:[AB_609894](https://scicrunch.org/resolver/AB_609894)                 IF (1:2000)

  Antibody                                     rabbit polyclonal anti-SFTPC                                        Merck-Millipore                                                                                                                                                                                                     Cat. \#: AB3786; RRID:[AB_91588](https://scicrunch.org/resolver/AB_91588)                  IF (1:500)

  Antibody                                     mouse monoclonal anti-KRT5 MA5-17057,                               Thermo Fisher Scientific                                                                                                                                                                                            Cat. \#: MA5-17057;\                                                                       IF (1:200)
                                                                                                                                                                                                                                                                                                                                       RRID:[AB_2538529](https://scicrunch.org/resolver/AB_2538529)                               

  Antibody                                     mouse monoclonal anti-CD45 FITC\                                    eBioscience                                                                                                                                                                                                         Cat. \#: 11-0451-85;\                                                                      FC (0,05 μg)
                                               conjugated                                                                                                                                                                                                                                                                              RRID:[AB_465051](https://scicrunch.org/resolver/AB_465051)                                 

  Antibody                                     mouse monoclonal anti-CD11b PE conjugated                           eBioscience                                                                                                                                                                                                         Cat. \#: 12-0112-82; RRID:[AB_2734869](https://scicrunch.org/resolver/AB_2734869)          FC (0,05 μg)

  Antibody                                     donkey polyclonal\                                                  Molecular Probes                                                                                                                                                                                                    Cat. \#: A21206; RRID:[AB_141708](https://scicrunch.org/resolver/AB_141708)                IF (1:500)
                                               anti-rabbit Alexa Fluor 488                                                                                                                                                                                                                                                                                                                                                        

  Antibody                                     donkey polyclonal anti-goat Alexa Fluor 568                         Molecular Probes                                                                                                                                                                                                    Cat. \#: A11057; RRID:[AB_142581](https://scicrunch.org/resolver/AB_142581)                IF (1:500)

  Antibody                                     donkey polyclonal anti-rabbit Alexa Fluor 647                       Molecular Probes                                                                                                                                                                                                    Cat. \#: A31573; RRID:[AB_2536183](https://scicrunch.org/resolver/AB_2536183)              IF (1:500)

  Antibody                                     donkey polyclonal anti-mouse Alexa Fluor 647                        Molecular Probes                                                                                                                                                                                                    Cat. \#: A31571; RRID:[AB_162542](https://scicrunch.org/resolver/AB_162542)                IF (1:500)

  Antibody                                     donkey polyclonal anti-mouse Alexa Fluor 568                        Abcam                                                                                                                                                                                                               Cat. \#: ab175700                                                                          IF (1:500)

  Sequence-based reagent                       Digital droplet PCR primers                                         This paper                                                                                                                                                                                                          Kras^Q61R^ mutation detection                                                              Forward: ATCTGACGTGCTTTGCCTGT, Reverse: CCCTCCCCAGTTCTCATGTA

  Sequence-based reagent                       Digital droplet PCR probe                                           This paper                                                                                                                                                                                                          Kras^Q61R^mutation detection                                                               sequence:\
                                                                                                                                                                                                                                                                                                                                                                                                                                  GACACAGCAGGTCAAGAGGAGTACA

  Sequence-based reagent                       Digital droplet PCR primers and probe                               Bio-Rad Laboratories                                                                                                                                                                                                Registration \#: dCNS685684912                                                             Tomato allele detection

  Sequence-based reagent                       Quantitative PCR                                                    This paper                                                                                                                                                                                                          *Scgb1a1* gene                                                                             Forward: ATCACTGTGGTCATGCTGTCC, Reverse: GCTTCAGGGATGCCACATAAC

  Sequence-based reagent                       Quantitative PCR                                                    This paper                                                                                                                                                                                                          *Sftpc* gene                                                                               Forward: TCGTTGTCGTGGTGATTGTAG, Reverse: TCGTTGTCGTGGTGATTGTAG

  Sequence-based reagent                       Quantitative PCR                                                    This paper                                                                                                                                                                                                          *Gusb* gene                                                                                Forward: TTACTTTAAGACGCTGATCACC, Reverse: ACCTCCAAATGCCCATAGTC

  Commercial assay or kit                      GenElute Mammalian Genomic DNA Minipreps Kit                        Sigma-Aldrich                                                                                                                                                                                                       Cat. \#: G1N70                                                                             

  Commercial assay or kit                      RNeasy Mini Kit                                                     Qiagen                                                                                                                                                                                                              Cat. \#: 74106                                                                             

  Commercial assay or kit                      SYBR FAST qPCR Kit                                                  Kapa Biosystems                                                                                                                                                                                                     Cat. \#: KK4600                                                                            

  Commercial assay or kit                      MycoAlert Mycoplasma Detection Kit                                  LONZA                                                                                                                                                                                                               Cat. \#: LT07-318                                                                          

  Chemical compound, drug                      Urethane, ethyl carbamate (EC)                                      Sigma-Aldrich                                                                                                                                                                                                       Cat. \#: U2500                                                                             1 g/Kg

  Chemical compound, drug                      3-methylcholanthrene (MCA)                                          Sigma-Aldrich                                                                                                                                                                                                       Cat. \#: 442388                                                                            15 mg/Kg

  Chemical compound, drug                      Butylated hydroxytoluene (BHT)                                      Sigma-Aldrich                                                                                                                                                                                                       Cat. \#: W218405                                                                           200 mg/Kg

  Chemical compound, drug                      Naphthalene                                                         Sigma-Aldrich                                                                                                                                                                                                       Cat. \#: 84679                                                                             250 mg/Kg

  Chemical compound, drug                      Bleomycin A2                                                        Calbiochem                                                                                                                                                                                                          Cat. \#: 203401                                                                            0.08 units

  Software, algorithm                          Transcriptome Analysis Console Software                             <https://www.thermofisher.com/tw/zt/home/life-science/microarray-analysis/microarray-analysis-instruments-software-services/microarray-analysis-software/affymetrix-transcriptome-analysis-console-software.html>   RRID:[SCR_016519](https://scicrunch.org/resolver/SCR_016519)                               

  Software, algorithm                          FlowJo software                                                     TreeStar                                                                                                                                                                                                            RRID:[SCR_008520](https://scicrunch.org/resolver/SCR_008520)                               

  Software, algorithm                          FloMax Software                                                     Partec                                                                                                                                                                                                              RRID:[SCR_014437](https://scicrunch.org/resolver/SCR_014437)                               

  Software, algorithm                          Broad Institute pre-ranked GSEA module software                     <http://software.broadinstitute.org/gsea/index.jsp>                                                                                                                                                                                                                                                            [@bib45]

  Software, algorithm                          NRECON software                                                     Bruker                                                                                                                                                                                                                                                                                                         

  Software, algorithm                          CT analysis (Ctan) software                                         Bruker                                                                                                                                                                                                                                                                                                         

  Software, algorithm                          CTVox software                                                      Bruker                                                                                                                                                                                                                                                                                                         

  Software, algorithm                          QuantaSoft                                                          Bio-Rad Laboratories (<http://www.bio-rad.com/en-gr/sku/1864011-quantasoft-software-regulatory-edition?ID=1864011>)                                                                                                                                                                                            

  Software, algorithm                          G\*power                                                            <http://www.gpower.hhu.de/>                                                                                                                                                                                         RRID:[SCR_013726](https://scicrunch.org/resolver/SCR_013726)                               [@bib12]

  Software, algorithm                          GraphPad Prism                                                      <http://www.graphpad.com/>                                                                                                                                                                                          RRID:[SCR_002798](https://scicrunch.org/resolver/SCR_002798)                               Version 8

  Software, algorithm                          Fiji                                                                <http://fiji.sc>                                                                                                                                                                                                    RRID:[SCR_002285](https://scicrunch.org/resolver/SCR_002285)                               PMID: [22743772](https://www.ncbi.nlm.nih.gov/pubmed/22743772)

  Software, algorithm                          Living Image software                                               Perkin-Elmer (<http://www.perkinelmer.com/catalog/category/id/living%20image%20software>)                                                                                                                           RRID:[SCR_014247](https://scicrunch.org/resolver/SCR_014247)                               Version 4.2

  Other                                        Microarray data                                                     This paper                                                                                                                                                                                                          Gene Expression Omnibus (GEO) accession ID: GSE94981                                       LUAD cells, bone marrow derived macrophages (BMDM), and tracheal AEC cells

  Other                                        Microarray data                                                     Gene Expression Omnibus (GEO)                                                                                                                                                                                       Accession ID: GSE82154; GSE55459; GSE46749; GSE18816; GSE43458                             *M. musculus* ATII cells; *H. sapiens* AEC cells; *H. sapiens* ATII cells;*H. sapiens*AMΦ; *H. sapiens* non-smokers lung and LUAD

  Other                                        GeneChip Mouse Gene 2.0 ST array; GeneChip Human Gene1.0 ST array   Thermo Fisher Scientific                                                                                                                                                                                            Cat. \#: 902119; Cat. \#: 901085                                                           

  Other                                        Hoechst33258 nuclear dye                                            Sigma-Aldrich                                                                                                                                                                                                       Cat. \#: 14530                                                                             1:5000

  Other                                        D-Luciferin potassium salt                                          Gold Biotechnology                                                                                                                                                                                                  Cat. \#: LUCK-100                                                                          1 mg

  Other                                        Trizol                                                              Thermo Fisher Scientific                                                                                                                                                                                            Cat. \#: 15596026                                                                          
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Key resources table {#s4-1}
-------------------

All raw data used to generate the main Figures and Figure Supplements are provided as \*.xlsx Source Data files.

Study approval {#s4-2}
--------------

All mice were bred at the Center for Animal Models of Disease of the University of Patras. Experiments were designed and approved *a priori* by the Veterinary Administration of the Prefecture of Western Greece (approval numbers 3741/16.11.2010, 60291/3035/19.03.2012, and 118018/578/30.04.2014) and were conducted according to Directive 2010/63/EU (<http://eur-lex.europa.eu/legal-content/EN/TXT/?qid=1486710385917&uri=CELEX:32010L0063>). Male and female experimental mice were sex-, weight (20--25 g)-, and age (6--12 week)-matched. *n* = 588 experimental and *n* = 165 breeder mice were used for this report. Sample size was calculated using power analysis on G\*power. Experiments were randomized across different cages and mouse lungs were always examined by two blinded researchers. Sample numbers are included in the figures and figure legends. Archival tissue samples of patients with LUAD ([@bib16]) that underwent surgical resection with curative intent between 2001 and 2008 at the University Hospital of Patras were retrospectively enrolled. The observational protocol for these studies adhered to the Helsinki Declaration and was approved by the Ethics Committee of the University Hospital of Patras, and all patients gave written informed consent.

Reagents {#s4-3}
--------

Urethane, ethyl carbamate, EC, CAS\# 51-79-6; 3-methylcholanthrene, 3-methyl-1,2-dyhydrobenzo\[j\]aceanthrylene, MCA, CAS\# 56-49-5; butylated hydroxytoluene, 2,6-Di-tert-butyl-4-methylphenol, BHT, CAS\# 128-37-0; naphthalene, CAS\# 91-20-3, and Hoechst33258 nuclear dye (CAS\# 23491-45-4), were from Sigma-Aldrich (St. Louis, MO). Bleomycin A2, ((3-{\[(2\'-{(5S,8S,9S,10R,13S)−15-{6-amino-2- \[(1S)−3-amino-1-{\[(2S)−2,3-diamino-3-oxopropyl\]amino}−3-oxopropyl\] −5-methylpyrimidin-4-yl}−13-\[{\[(2R,3S,4S,5S,6S)−3-{\[(2R,3S,4S,5R,6R)−4-(carbamoyloxy)−3,5-dihydroxy-6- (hydroxymethyl) tetrahydro-2H-pyran-2-yl\]oxy} −4,5-dihydroxy-6-(hydroxymethyl) tetrahydro-2H-pyran-2-yl\]oxy} (1H-imidazol-5-yl)methyl\]−9-hydroxy-5-\[(1R)−1-hydroxyethyl\]−8,10-dimethyl-4,7,12,15-tetraoxo-3,6,11,14-tetraazapentadec-1-yl}−2,4\'-bi-1,3-thiazol-4-yl)carbonyl\]amino}propyl) (dimethyl)sulfonium; CAS \#9041-93-4, was from Calbiochem (Darmstadt, Germany). D-Luciferin potassium salt, (4S)−2-(6-hydroxy-1,3-benzothiazol-2-yl)−4,5-dihydrothiazole-4-carboxylic acid, CAS \#2591-17-5, was from Gold Biotechnology (St. Louis, MO).

Experimental mice {#s4-4}
-----------------

C57BL/6J (C57BL/6; \#000664), FVB/NJ (FVB; \#001800), *B6.129(Cg)-Gt(ROSA)26Sor^tm4(ACTB-tdTomato,-EGFP)Luo^/J* \[mT/mG; TOMATO; \#007676; ([@bib34])\], *FVB.129S6(B6)-Gt(ROSA)26Sor^tm1(Luc)Kael^/J* \[LUC; \#005125; ([@bib41])\], *B6.129P2-Gt(ROSA)26Sor^tm1(DTA)Lky^/J* \[DTA; \#009669; ([@bib52])\], *B6.129P2-Lyz2^tm1(cre)Ifo^/J* \[LYZ2.CRE; \#004781; ([@bib11])\], *B6.Cg-Tg(Sox2-cre)1Amc/J* \[SOX2.CRE; \#008454; ([@bib17])\], *B6.Cg-Tg(Vav1-icre)A2Kio/J* \[VAV.CRE; \#008610; ([@bib37])\], and *B6.Cg-Tg(Nes-cre)1Kln/J* \[NES.CRE; \#003771; ([@bib50])\] mice were from Jackson Laboratories (Bar Harbor, MN). *B6;CBA-Tg(Scgb1a1-cre)1Vart/Flmg* (CCSP.CRE; European Mouse Mutant Archive \#EM:04965) mice are described elsewhere ([@bib38]) and *Tg(Sftpc-cre)1Blh* (SFTPC.CRE; Mouse Genome Informatics \#MGI:3574949) mice were donated by their founder ([@bib39]). Mice were bred \>F12 to the FVB background at the University of Patras Center for Animal Models of Disease.

Mouse models of lung adenocarcinoma {#s4-5}
-----------------------------------

Six-week-old mice on the C57BL/6 background received ten consecutive weekly intraperitoneal urethane injections (1 g/Kg in 100 μL saline) and were sacrificed 6--7 months after the first injection, or four consecutive weekly intraperitoneal MCA (15 mg/Kg in 100 μL saline) followed by eight consecutive weekly intraperitoneal BHT injections (200 mg/Kg in 100 μL corn oil) and were sacrificed 6--7 months after the first injection. Six-week-old mice on the FVB background received one intraperitoneal urethane injection (1 g/Kg in 100 μL saline) and were sacrificed 6--7 months later ([@bib54]; [@bib33]; [@bib29]; [@bib44]; [@bib53]).

Mouse models of lung injury {#s4-6}
---------------------------

Six-week-old mice (C57BL/6 background) received intratracheal bleomycin A2 (0.08 units in 50 μL saline) or intraperitoneal naphthalene (250 mg/Kg in 100 μL corn oil) ([@bib24]; [@bib40]). In addition, preterm mothers of the C57BL/6 background and their offspring were exposed to room air (21% oxygen; control) or 98% oxygen for two days before and four days after birth ([@bib40]; [@bib57]). Oxygen levels were continuously monitored. The gas stream was humidified to 40--70% by a deionized water-jacketed Nafion membrane tubing and delivered through a 0.22 μm filter before passage into a sealed Lexan polycarbonate chamber measuring 40 × 25×25 cm and accommodating 25 L gas at a flow rate of 5 L/min, resulting in complete gas exchange every 5 min. Mothers were cycled between litters on 21% and 98% oxygen every 24 hr to prevent oxygen toxicity and to control for nutritional support of the pups. After perinatal hyperoxia, mice remained at room air till sacrificed at eight weeks of age.

Urethane-induced lung adenocarcinoma cell lines {#s4-7}
-----------------------------------------------

Lung tumors were dissected from surrounding healthy lung parenchyma under sterile conditions, minced into 1 mm pieces, and cultured at 37°C in 5% CO~2~--95% air using Dulbecco's Modified Eagle Medium (DMEM), 10% FBS, 2 mM L-glutamine, 1 mM pyruvate, 100 U/mL penicillin, and 100 U/mL streptomycin. All cell lines were immortal and indefinitely phenotypically stable over \>18 months and/or 60 passages, and were tumorigenic and metastatic in C57BL/6 mice ([@bib22]). Cell lines were cultured in DMEM supplemented with 10% FBS and 100 IU/mL penicillin/streptomycin and were maintained in humidified incubators at 37°C with 95% air--5% CO~2~. Cell lines were authenticated annually using the short tandem repeat method and were tested negative for *Mycoplasma Spp.* biannually by MycoAlert Mycoplasma Detection Kit (LONZA; Verviers, Belgium).

Human lung adenocarcinomas {#s4-8}
--------------------------

Ten archival formalin-fixed, paraffin-embedded tissue samples of patients with LUAD that underwent surgical resection with curative intent between 2001 and 2008 at the University Hospital of Patras were retrospectively enrolled ([@bib16]). The observational protocol for these studies adhered to the Helsinki Declaration and was approved by the Ethics Committee of the University Hospital of Patras, and all patients gave written informed consent.

Micro-computed tomography {#s4-9}
-------------------------

Urethane or saline treated FVB mice were sacrificed six months post urethane/saline injection. Lungs were inflated and fixed with 10% neutral buffered formalin overnight. They were then dehydrated and chemically dried for μCT scanning using a method kindly provided by Jeroen Hostens (Bruker; Kontich, Belgium). Briefly, a gradient ethanol dehydration protocol (from 70--100%) was applied, followed by 2 hr incubation in Hexamethyldisilazane (HMDS; Sigma, St. Louis, MO) and 2 hr air-drying. The dehydrated lungs were then scanned in a Bruker SkyScan 1172 scanner at 41kV without filtration and with 5.94 μm voxel resolution (exposure: 440 ms). The X-ray projections were obtained at 0.35° intervals with a scanning angular rotation of 180° and two frames were averaged for each rotation under a mean of 10 frames per random movement. 3D reconstructions were performed using NRECON software (Bruker). Regions of interest for the whole lung and peripheral lung tissue were defined in the CT analysis software (CTan; Bruker), thresholds applied to detect tissue from background, and a 3D volume rendering of the lungs were performed using the CTVox software (Bruker).

Structural assessments in murine lungs {#s4-10}
--------------------------------------

Mouse lungs were recoded (blinded) by laboratory members not participating in these studies and were always examined by two independent blinded participants of this study. The results obtained by each investigator were compared, and lungs were re-evaluated if deviant by \>20%. Lungs and lung tumors were initially inspected macroscopically under a Stemi DV4 stereoscope equipped with a micrometric scale incorporated into one eyepiece and an AxiocamERc 5 s camera (Zeiss, Jena, Germany) in trans-illumination mode, allowing for visualization of both superficial and deeply-located lung tumors ([@bib44]; [@bib53]). Tumor location was charted and diameter (δ) was measured. Tumor number (multiplicity) per mouse was counted and mean tumor diameter per mouse was calculated as the average of individual diameters of all tumors found in a given mouse lung. Individual tumor volume was calculated as πδ^3^/6. Mean tumor volume per mouse was calculated as the average of individual volumes of all tumors found in a given mouse lung, and total lung tumor burden per mouse as their sum. Following macroscopic mapping of lung and lung tumor morphology, lungs of fluorescent reporter mice were imaged on a Leica MZ16F fluorescent stereomicroscope equipped with GFP and RFP filters and a DFC 300FX camera (Leica Microsystems, Heidelberg, Germany) in order to determine their macroscopic fluorescent pattern. Lung volume was measured by saline immersion, and lungs were embedded in paraffin, randomly sampled by cutting 5 μm-thick lung sections (*n* = 10/lung), mounted on glass slides, and stained with hematoxylin and eosin for morphometry and histologic typing of lung tumors. For this, a digital grid of 100 intersections of vertical lines (points) was superimposed on multiple digital images of all lung sections from lung tissue of a given mouse using Fiji academic freeware (<https://fiji.sc/>). Total lung tumor burden was determined by point counting of the ratio of the area occupied by neoplastic lesions versus total lung area and by extrapolating the average ratio per mouse to total lung volume ([@bib19]). The results of this stereologic approach were compared with the macroscopic method, and were scrutinized if deviant by \>20%. To evaluate alveolar structure and size, we calculated mean linear intercept using randomly sampled hematoxylin and eosin-stained lung sections, as described elsewhere ([@bib19]). For this, a digital grid of twenty random horizontal lines was superimposed on multiple digital images of all lung sections from lung tissue of a given mouse using Fiji. Mean linear intercept was calculated by counting the intercepts of interalveolar septae with the lines and the formula: Σ{2 x (length of line/number of intercepts)}/total number of lines. All quantifications were done by counting at least five random non-overlapping fields of view of at least ten sections per lung.

Histology and molecular phenotyping {#s4-11}
-----------------------------------

For histology, lungs were inflated to 20 cmH~2~O pressure that provides for a lung volume equivalent to the resting volume of the lungs (a.k.a. functional residual capacity in humans) and enables precise histologic observations on airway and alveolar structure avoiding false interpretations resulting from the study of compressed or over-inflated lungs ([@bib19]). Subsequently, lungs were fixed with 10% formalin overnight and were embedded in paraffin. Five-μm-thick paraffin sections were then counterstained with hematoxylin and eosin (Sigma, St. Louis, MO) and mounted with Entellan New (Merck Millipore, Darmstadt, Germany). For immunofluorescence, lungs were inflated with a 2:1 mixture of 4% paraformaldehyde:Tissue-Tek (Sakura, Tokyo, Japan), fixed in 4% paraformaldehyde overnight at 4°C, cryoprotected with 30% sucrose, embedded in Tissue-Tek and stored at −80°C. Ten-μm cryosections were then post-fixed in 4% paraformaldehyde for 10 min, treated with 0.3% Triton X‐100 for 5 min, and incubated in blocking solution containing 10% fetal bovine serum (FBS), 3% bovine serum albumin (BSA), 0.1% polyoxyethylene (20) sorbitanmonolaurate (Tween 20) in 1x phosphate-buffered saline (PBS) for 1 hr. Following labeling with the indicated primary antibodies overnight at 4°C, sections were incubated with fluorescent secondary antibodies, counterstained with Hoechst 33258 and mounted with Mowiol 4--88 (Calbiochem, Darmstadt, Germany). The following primary antibodies were used: rabbit anti-proliferating cell nuclear antigen (PCNA, 1:3000 dilution, ab2426, Abcam, London, UK), rabbit anti-LYZ2 (1:50 dilution, ab108508, Abcam), rabbit anti-KRT5 (1:200 dilution, ab53121, Abcam), rabbit anti-SFTPC (1:200 dilution, sc-13979, Santa Cruz, Dallas, TX), rabbit anti-CCSP (1:200 dilution, sc-25555, Santa Cruz), goat anti-CCSP (1:1000 dilution, sc-9772, Santa Cruz), mouse anti-acetylated α-tubulin (1:2000 dilution, T7451, Sigma-Aldrich, St. Lewis, MO), rabbit anti-SFTPC (1:500 dilution, AB3786, Merck-Millipore, Burlington, MA), and mouse anti-KRT5 (1:200 dilution, MA5-17057, Thermo Fisher Scientific, Waltham, MA). Alexa Fluor donkey anti-rabbit 488 (A21206, Thermo Fisher Scientific), Alexa Fluor donkey anti-mouse 568 (ab175700, Abcam), Alexa Fluor donkey anti-goat 568 (A11057, Thermo Fisher Scientific), Alexa Fluor donkey anti-rabbit 647 (A31573, Thermo Fisher Scientific), and Alexa Fluor donkey anti-mouse 647 (A31571, Thermo Fisher Scientific) secondary antibodies were used at 1:500 dilution. For isotype control, the primary antibody was omitted. Bright-field images were captured with an AxioLab.A1 microscope connected to an AxioCamERc 5 s camera (Zeiss, Jena, Germany) whereas fluorescent microscopy was carried out either on an Axio Observer D1 inverted fluorescent microscope (Zeiss, Jena, Germany) or a TCS SP5 confocal microscope (Leica Microsystems, Wetzlar, Germany) with 20x, 40x and 63x lenses. Digital images were processed with Fiji. All quantifications of cellular populations were obtained by counting at least five random non-overlapping bronchial-, alveolar-, hyperplasia-, or tumor- containing fields of view per section.

Pulmonary function testing {#s4-12}
--------------------------

Following anesthesia induced by intraperitoneal ketamine (100 mg/Kg) and xylazine (10 mL/Kg) and tracheostomy, mice were mechanically ventilated by a Flexivent rodent ventilator (Scireq, Montreal, Ontario, Canada). The whole procedure, described elsewhere ([@bib30]), lasted 15 min. After a 3 min run-in period of ventilation with 21% oxygen, a tidal volume of 10 mL/Kg, a respiratory rate of 150 breaths/min, and a positive end-expiratory pressure of 3 cmH~2~O, paralysis was induced using 8 mg/Kg intraperitoneal succinyl choline, and total respiratory system impedance was obtained by applying an 8-sec-long pseudorandom frequency oscillation (0.5--19.75 Hz) to the airway opening. Thirty seconds prior to initiation of measurements, lung volume history was once controlled by a 6-sec-long inflation to 30 cm H~2~O pressure. Measurements were repeated thrice at 60 s intervals and were averaged. Data were fit into the constant phase model in order to fractionate total respiratory input impedance into airways resistance (Raw) and tissue damping and elastance coefficients. To obtain pressure-volume (PV) curves, the respiratory system was incrementally inflated and deflated to 40 mL/Kg total volume at seven steps each and airway pressures were recorded on each volume change. The slope of the linear portion of expiratory PV curves, which represents static compliance (Cst), a measure of airspace function, was calculated manually. Operators were blinded to animal genotype.

Digital droplet (dd)PCR {#s4-13}
-----------------------

TOMATO, GFP;CCSP.CRE, and GFP;LYZ2.CRE mice (FVB strain) received one intraperitoneal injection of urethane (1 g/Kg) and lungs were then harvested one and two weeks post-urethane, homogenized, and subjected to DNA extraction and purification using GenElute Mammalian Genomic DNA Miniprep Kit (Sigma-Aldrich, St. Louis, MO). DNA concentration and quality were assessed using a Nanodrop 1000 spectrophotometer (Thermo Fisher Scientific,Waltham, MA). DNA concentration was converted to number of diploid copies according to the formula: DNA (ng/µL)/weight of mouse diploid genome (3.9 pg). Digital droplet PCR protocol and analysis was performed as described previously using reagents, equipment and software from BioRad Laboratories Inc (Hercules, CA) ([@bib32]). In brief, 20000 genome copies were used. Samples were normalized internally according to the number of accepted droplets and inter-sample normalization was performed according to the formula \[x-min(x)\]/\[max(x)-min(x)\],where x represents the actual, min(x) the minimum, and max(x) the maximum number of accepted droplets. The data were reported as % positive/accepted droplets. Sequences of *Kras*^Q61R^ primers and probe were: *Kras*^Q61R^ forward: ATCTGACGTGCTTTGCCTGT, *Kras*^Q61R^ reverse: CCCTCCCCAGTTCTCATGTA, and *Kras*^Q61R^ probe: GACACAGCAGGTCAAGAGGAGTACA. The *Rosa^mT^* assay is registered as dCNS685684912 (Bio-Rad) with MIQE context: seq1:195--315:+CCAGTTCATGTACGGCTCCAAGGCGTACGTGAAGCACCCCGCCGACATCCCCGATTACAAGAAGCTGTCCTTCCCCGAGGGCTTCAAGTGGGAGCGCGTGATGAACTTCGAGGACGGCGGTCT. Primers and fluorescently labeled probes were combined in a mixture containing 18 μM forward and reverse primers and 5 μM labeled probes (20x primer/Taqman probe mix). Reactions were assembled to contain 12.5 μL 2x ddPCR mix no-UTP, 1.25 μL 20x *Kras*^Q61R^primer/Taqman probe Mix, 1.25 μL 20x *Rosa^mT^* custom primer/Taqman probe Mix and 10 μL DNA diluted in nuclease-free water. The ddPCR protocol included a first denaturation step at 95°C for 10 min followed by 40 cycles of denaturation at 95°C for 30 s and 40 cycles of annealing at 62.5°C for 60 s, and was performed in a BioRad T100 Thermal cycler. Results were analyzed with a BioRad QX100 droplet reader using the QuantaSoft software. The amplitude gathering thresholds of positive droplets were set at 3500 for the *Rosa^mT^* and at 10000 for the *Kras*^Q61R^ probe, according to the manufacturer's instructions.

Bronchoalveolar lavage (BAL) {#s4-14}
----------------------------

BAL was performed using three sequential aliquots of 1000 µL sterile ice-cold phosphate-buffered saline (PBS). Fluid was combined and centrifuged at 260 g for 10 min to separate cells from supernatant. The cell pellet was resuspended in 1 ml PBS containing 2% fetal bovine serum, and the total cell count was determined using a grid hemocytometer according to the Neubauer method. Cell differentials were obtained by counting 400 cells on May-Grünwald-Giemsa-stained cytocentrifugal specimens. Total BAL cell numbers were calculated by multiplying the percentage of each cell type by total BAL cell number ([@bib44]; [@bib53]).

Bioluminescence imaging {#s4-15}
-----------------------

LUC;CCSP.CRE mice, bioluminescent reporters of CCSP-labeled cell mass, received one intraperitoneal injection of saline (100 μL saline) or urethane (1 g/Kg in 100 μL saline) and were serially imaged before treatment start, and at 150 and 210 days into treatment. Imaging was done on a Xenogen Lumina II (Perkin-Elmer, Waltham, MA) 5--20 min after delivery of 1 mg D-Luciferin sodium in 100 μL of sterile water to the retro-orbital vein, and data were analyzed using Living Image v.4.2 (Perkin-Elmer, Waltham, MA) ([@bib44]; [@bib53]).

qPCR and microarrays {#s4-16}
--------------------

Triplicate cultures of 10^6^ LUAD cells, BMDM (obtained by 1 week bone marrow incubation with 100 ng/mL M-CSF), and tracheal AEC (obtained by 1 week incubation of stripped mouse tracheal epithelium in DMEM) were subjected to RNA extraction using Trizol (Thermo Fisher) followed by column purification and DNA removal (Qiagen, Hilden, Germany). Whole lungs were homogenized in Trizol followed by the same procedure. Pooled RNA (5 μg) was quality tested (ABI 2000 Bioanalyzer; Agilent Technologies, Sta. Clara, CA), labeled, and hybridized to GeneChip Mouse Gene 2.0 ST arrays (Affymetrix, Sta. Clara, CA). All data were deposited at GEO (<http://www.ncbi.nlm.nih.gov/geo/>; Accession ID: GSE94981) and were analyzed on the Affymetrix Expression and Transcriptome Analysis Consoles together with previously reported ([@bib14]; [@bib21]; [@bib9]; [@bib10]; [@bib25]) murine ATII and human AEC, ATII, AMΦ, non-smokers lung, and LUAD microarray data (Accession IDs: GSE82154, GSE55459, GSE46749, GSE18816, GSE43458). qPCR was performed using first strand synthesis with specific primers (*Scgb1a1*: ATCACTGTGGTCATGCTGTCC and GCTTCAGGGATGCCACATAAC; *Sftpc*: TCGTTGTCGTGGTGATTGTAG and AGGTAGCGATGGTGTCTGCT; *Gusb*: TTACTTTAAGACGCTGATCACC and ACCTCCAAATGCCCATAGTC) and SYBR FAST qPCR Kit (Kapa Biosystems, Wilmington, MA) in a StepOne cycler (Applied Biosystems, Carlsbad, CA). Ct values from triplicate reactions were analyzed with the 2^-ΔCT^ method relative to *Gusb*.

Flow cytometry {#s4-17}
--------------

BAL cells were suspended in 50 μL PBS with 2% FBS and 0.1% NaN~3~, were stained with anti-CD45 (\#11-0451-85; eBioscience; Santa Clara, CA) and anti-CD11b (\#12-0112-82; eBioscience; Santa Clara, CA) primary antibodies for 20 min in the dark at 0.5 μL antibody per million cells, and were analyzed on a CyFlowML cytometer with a sorter module using FloMax Software (Partec, Darmstadt, Germany) or FlowJo software (TreeStar, Ashland, OR), as described previously ([@bib22]). Perfused lungs were digested in RPMI-1640 medium containing collagenase XI (0.7 mg/mL; Sigma, St. Louis, MO) and type IV bovine pancreatic DNase (30 μg/mL; Sigma, St. Louis, MO) to obtain single-cell suspensions. After treatment with red blood cell lysis buffer (BioLegend; San Diego, CA), single-cell suspensions were analyzed on a LSR II flow cytometer (BD Bioscience, San Diego, CA), and data were examined with FlowJo. Dead cells were excluded using 4,6-diamidino-2-phenylindole (DAPI; Sigma, St. Louis, MO).

Microarray and gene set enrichment analyses (GSEA) {#s4-18}
--------------------------------------------------

GSEA was performed with the Broad Institute pre-ranked GSEA module software (<http://software.broadinstitute.org/gsea/index.jsp>) ([@bib45]). In detail, genes significantly expressed (log2 normalized expression \>8) in murine tracheal airway cells, ATII cells ([@bib14]), and BMDM were cross-examined against the murine lung and chemical-induced LUAD cell line transcriptomes. In addition, previously reported human AEC, ATII, and AMΦ cellular signatures ([@bib9]; [@bib10]; [@bib25]) were cross-examined against the previously described transcriptomes of human normal lung tissue from never-smokers and of LUAD ([@bib21]).

Statistical analysis {#s4-19}
--------------------

Sample size was calculated using power analysis on G\*power (<http://www.gpower.hhu.de/>), assuming *α* = 0.05, *β* = 0.05, and effect size *d* = 1.5 ([@bib12]). No data were excluded from analyses. Animals were allocated to treatments by alternation and transgenic animals were enrolled case-control-wise. Data were collected by at least two blinded investigators from samples coded by non-blinded investigators. All data were normally distributed by Kolmogorov-Smirnov test, are given as mean ± SD, and sample size (*n*) always refers to biological and not technical replicates. Differences in frequency were examined by Fischer's exact and χ^2^ tests and in means by t-test or one-way ANOVA with Bonferroni post-tests. Changes over time and interaction between two variables were examined by two-way ANOVA with Bonferroni post-tests. All probability (*P*) values are two-tailed and were considered significant when p\<0.05. All analyses and plots were done on Prism v8.0 (GraphPad, La Jolla, CA).

Data availability {#s4-20}
-----------------

All raw data produced in this study are provided as \*.xlsx source data supplements. The microarray data produced by this study were deposited at GEO (<http://www.ncbi.nlm.nih.gov/geo/>; Accession ID: GSE94981). Previously reported murine ATII and human AEC, ATII, AMΦ, non-smokers lung, and LUAD microarray data are available at GEO using Accession IDs GSE82154, GSE55459, GSE46749, GSE18816, and GSE43458).
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"Dual airway and alveolar contributions to adult lung homeostasis and carcinogenesis\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers and the evaluation has been overseen by a Reviewing Editor and Jeffrey Settleman as the Senior Editor. The following individual involved in the review of your submission has agreed to reveal their identity: York Miller (Reviewer \#3).

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission. While the reviews are generally positive about the findings, all reviewers are united on the view that the manuscript requires a substantial rewrite, as it was incredibly difficult to understand, full of jargon, and is written for an extremely specialist audience, rather than the general readership at *eLife*. Therefore, we offer you the opportunity to rewrite the manuscript in a more general way, with good descriptors of each cell type and labels for them, rather than specific markers. Compared to the main text having too many specific markers, the title is too general and does not state clearly what the novelty of the findings are. We will consider the revised manuscript for publication only if we feel that you can communicate it to a wider audience.

For assistance, York has kindly offered a brief descriptor of what he believes the novelty of the findings are and ways that the text could be improved:

1\) They show that mouse lung adenocarcinomas do largely arise from cells expressing a Club cell marker, not those derived from ATII cells. This is done by the lineage tracing, by morphometry and imaging of early tumors and by ablation using targeted expression of diphtheria toxin. These extend and modify previous studies by Carla Kim using IHC and ISH. The importance of this is that if we are going to target early premalignancy, strategies focused on Club cells seem more promising than those targeting ATII cells.

2\) Most interesting was the finding that both ATII and Club type cells carry KRAS mutations shortly after urethane carcinogenesis, but that the mutated ATII cells become extinct while the Club cells persist and evolve into adenocarcinomas.

3\) There is some transcriptomic evidence to suggest that a similar situation exists in human lung adenocarcinoma. Clearly this is not as rigorous as can be demonstrated in the mouse.

There are several ways this can be greatly improved.

1\) Define abbreviations early in manuscript and provide some guidance as to what the import of these markers is.

2\) Figures are very small and hard to follow. Unfortunately, this is common across a lot of current literature as authors try to jam a large amount of experimental work into a small space.

3\) Some of the figures, such as the one showing the KRAS mutation in ATII and Club cells, could be simplified. The time course graph here is most important.

4\) Provide a better introduction to the abbreviations and markers for readers not intimately knowledgeable about this field.

These are a summary of the main points that we will need for you to revise. I include the full reviews of the reviewers, which may also help you to rewrite the paper for your reference alone.

*Reviewer \#1:*

The manuscript, \"Dual airway and alveolar contributions to adult lung homeostasis and carcinogenesis\" by Spella et al., employ specific cell labeling and transcriptomics to identify airway cell types in developing versus wounded versus carcinogen-induced adenocarcinoma induction. Overall, they find that \'airway cells\' are required for alveolar maintenance and lung carcinoma development. While the results documented in this manuscript could be compelling and many of the questions that they are asking are fundamental questions in biology and cancer, the written paper and figures were so hard to read that I cannot interpret them. There are no clues to all the acronyms and markers the authors use throughout the paper until potentially the summary at the last figure. It is not the job of the reader to do all the background reading to try to understand what the authors may or may not be trying to say. Therefore, while their findings may be compelling, the authors must find a way to relay a coherent story that is understandable to the wide audience at *eLife*.

Additionally, I have a few comments, based on what I think I may have interpreted correctly.

1\) Is it really interesting to find that, \"Collectively, these results indicate that airway cells and/or transcriptomic signatures are essential for alveolar maintenance and LUAD development.\"? Are cells not within the airway expected to contribute to airway development and cancer. Again, this may lie within code words used between people in the lab that they haven\'t explained to other people. To me, airway cells include all cells within the airway, including stroma.

2\) I think that the findings that carcinogenesis could come from faulty repopulation of adult cells following the continuous wounding of airway epithelia to be the most interesting finding of this study, yet it is not tackled directly. Is this something that the authors are saying?

3\) The main problem with the paper is that the authors are using drivers of cell lines that they never describe or confirm with markers that are clearly labeled and cited. The reader has no idea what cells they are labeling with what driver and how we know that the labels are acceptable. Without this, the whole study could be a house of cards with interpretations depending on whatever they have decided to call cells.

4\) They need to find a way to write in a way that captures the reader\'s attention so that we understand right upfront what the problem is that they are trying to address and how they will approach it. They could put the drivers and markers into a table, once they show clear evidence what cell type they refer to. Then refer only to the cell type in plain English, not a thousand acronyms.

5\) There seems to be a very fuzzy plot throughout. They are using cell lines, ablation of certain cells, Cre-labeled cells and then they come up with very fuzzy conclusions. They might do well to reduce what they are looking at and come up with clear questions to the answers that they think that the experiments answer.

*Reviewer \#2:*

The authors studied the distribution of airway cells in lung injury and repair including tumorigenesis. They characterized the dynamics of respiratory epithelial cells in the mouse lung during aging and after challenge with toxic and carcinogens. They developed Cre-reporter mice with the tomato (mT) to GFP (mG) fluorescence expression of six different Cre-driver genes, three of which were successful. They demonstrated expression in airway and alveolar cells at baseline and in chemical carcinogen induced lung ADC in FVB mT/mG mice expressing SCGB1a1 or Lyz2. They demonstrated dissemination of an \"airway transcriptomic signature\" in the alveoli of carcinogen treated mice by virtue of showing Scgbia1 cells to be CCSP+TUBA1A-SFTPC-. They demonstrated dynamic changes in cellular composition presumably induced by the field of cancerization -- tobacco. Scag1a1 cells proliferate after injury including bleomycin, hyperoxia and naphthalene. Lastly, they showed using Dta ablation model that both SCGB1a1 and Lyz2 driven cells are key for tumor development. In a series of clever experiments, they studied epithelial cell signatures, urethane induced in cancer cells vs tracheal explants and ATII cells, and BMDM. Lung ADCs lost expression of epithelial markers and gained EGFR, Myc and Krt18 markers. AEC (but not the ATII and AMΦ) signature was significantly enriched in LUAD compared with healthy lung tissue. AEC gene expression signature predominated over ATII and BMDM signatures in LUAD cells. Finally, the results indicate that both airway and alveolar-restricted programs are needed for structural and functional integrity.

Overall the paper is very interesting and loaded with information. The premise of the work is very strong: \"ablation of airway cells distorted alveolar structure and function and protected mice from LUAD development.\"

The authors should be commended for the novelty of the work and for the potentially transformative findings bringing the plasticity of the conducting airway epithelial cells to the forefront of lung homeostasis and tumorigenesis. The paper does nail down in mice what specific cell type(s) in the conducting airway is at stake.

The findings support that airway cells and/or transcriptomic signatures are essential for alveolar maintenance and LUAD development. This statement may be true in the mouse models generated but the evidence that would suggest that is can be true in humans is insufficiently developed.

\"The data indicate remarkable plasticity of adult lung epithelial cells and suggest a central role for airway cells and transcriptional signature (s)in lung regeneration and cancer\". It remains unclear as to whether these scgb1A1 cells are migrating to the alveolar space or rather expressing CCSP by regenerating alveolar cells. The question is not settled by the results of these experiments, yet it has huge implications. The data seem to further support the concept of trans-differentiation which is not addressed in the paper. Isolation and transcriptional profile at the single cell level may solve the question.

Upon exposure to urethane the Scgb1a1.cre;Dta and lyz2 were equally protected from developing lung ADC? Why would Lyz2 cells be needed for tumorigenesis is not clear.

The paper is not well written overall and was very challenging to read/ review. The paper is structured in such way that we discuss lung tumors than homeostasis and repair and back to lung ADC. It is quite difficult to follow. There are many grammatical errors and too many shortcuts for expressing new concepts. It would benefit from simplification and from focusing the report on the main findings.

*Reviewer \#3:*

The authors examine the evolution of chemically induced lung adenocarcinomas in three informative genetically marked mouse strains: Scgb1a1.Cre, Sftpc.Cre and Lyz2.Cre crossed with a reporter construct mediated by a permanent switch from membranous mT to mG. The genetic marking approach yields somewhat discordant results with immunostaining for marker proteins and provides evidence that airway epithelial cells (Scgb1a1 descendant) are critical in both airway and alveolar repair after injury as well as the development of adenocarcinoma precursors. They support this with both imaging and histochemical analyses that demonstrate a majority of adenocarcinomas appear to originate from airways, not alveoli. Additional evidence is added from diphtheria toxin mediated cell line ablation. Furthermore, they trace the timecourse of the urethane induced KRAS mutation in Scgb1a1 and Sftpc derived cells which demonstrates an impressive extinction of the latter and persistence of the former, raising interesting questions as to the selective pressures driving this evolution. Additional experiments describe the role of Scgb1a1 derived cells in aging and injury repair. To the extent possible, the authors support the relevance of their findings to human lung adenocarcinoma through transcriptomic analysis.

As I am not an expert in cell lineage tracing, there may be issues here which I have missed. I believe that the results provide strong support for the importance of airway epithelial cells, rather than alveolar type II cells, in the genesis of many lung adenocarcinomas. Why the KRAS mutation specifically caused by urethane is maintained in airway epithelial derived cells but is not in alveolar type II cells is fascinating. This is highly relevant to prevention and risk determination. I do not suggest any major additional work.

\[Editors\' note: further revisions were requested prior to acceptance, as described below.\]

Thank you for resubmitting your work entitled \"The conducting airway epithelium fosters chemical-induced lung adenocarcinoma and alveolar maintenance in adult mice.\" for further consideration at *eLife*. Your revised article has been favorably evaluated by Jeffrey Settleman (Senior Editor) and a Reviewing Editor.

The manuscript has been improved but there are some remaining issues that need to be addressed before acceptance, as outlined below:

The revised manuscript is much easier to read. My only remaining issue with the revised paper is that the Title and Abstract are still confusing. Title: The conducting airway epithelium (again that doesn\'t seem very specific) fosters (what does foster mean? usually it means to adopt for a short time or to nurture. It is still a vague word -- do you mean it acts like a seed or a soil? This is not a very cogent title and needs help). Additionally, the Abstract\'s last two sentences are a jumble. Why not break them up into different sentences so that each has a precise meaning. Finally, \'lucrative\'? Is that what is being learnt here? They could be lucrative cells? I think that this needs a good rewrite. My sense is that this is an important paper that should be published but it really deserves to be understood by its readers. Therefore, I have asked for a full copyedit and I think it would be good to make sure that you are stating everything you want to say, especially in the Title and the Abstract, which will get the most readership.

10.7554/eLife.45571.088

Author response

> The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission. While the reviews are generally positive about the findings, all reviewers are united on the view that the manuscript requires a substantial rewrite, as it was incredibly difficult to understand, full of jargon, and is written for an extremely specialist audience, rather than the general readership at eLife. Therefore, we offer you the opportunity to rewrite the manuscript in a more general way, with good descriptors of each cell type and labels for them, rather than specific markers. Compared to the main text having too many specific markers, the title is too general and does not state clearly what the novelty of the findings are. We will consider the revised manuscript for publication only if we feel that you can communicate it to a wider audience.

We are extremely thankful to you both and our reviewers for the time spent in reviewing our paper, the overall positive appraisal of our findings, and the constructive criticism that helped us immensely in improving the manuscript. We are especially thankful to Dr. York Miller, reviewer \#3, who provided additional feedback in order to help us re-write the paper. We have undertaken every effort feasible to address the editorial and reviewers' comments and are hereby submitting an overtly improved version of the paper, which we hope to be acceptable. In more detail, we have now completely re-written the manuscript and re-designed the figures in order to more effectively convey the findings to a broad readership. Violin plots were included in the new figures, which depict the raw data as well as their distribution.

> For assistance, York has kindly offered a brief descriptor of what he believes the novelty of the findings are and ways that the text could be improved:
>
> 1\) They show that mouse lung adenocarcinomas do largely arise from cells expressing a Club cell marker, not those derived from ATII cells. This is done by the lineage tracing, by morphometry and imaging of early tumors and by ablation using targeted expression of diphtheria toxin. These extend and modify previous studies by Carla Kim using IHC and ISH. The importance of this is that if we are going to target early premalignancy, strategies focused on Club cells seem more promising than those targeting ATII cells.
>
> 2\) Most interesting was the finding that both ATII and Club type cells carry KRAS mutations shortly after urethane carcinogenesis, but that the mutated ATII cells become extinct while the Club cells persist and evolve into adenocarcinomas.
>
> 3\) There is some transcriptomic evidence to suggest that a similar situation exists in human lung adenocarcinoma. Clearly this is not as rigorous as can be demonstrated in the mouse.
>
> There are several ways this can be greatly improved.
>
> 1\) Define abbreviations early in manuscript and provide some guidance as to what the import of these markers is.
>
> 2\) Figures are very small and hard to follows. Unfortunately, this is common across a lot of current literature as authors try to jam a large amount of experimental work into a small space.
>
> 3\) Some of the figures, such as the one showing the KRAS mutation in ATII and Club cells, could be simplified. The time course graph here is most important.
>
> 4\) Provide a better introduction to the abbreviations and markers for readers not intimately knowledgeable about this field.
>
> These are a summary of the main points that we will need for you to revise. I include the full reviews of the reviewers, which may also help you to rewrite the paper for your reference alone.

We carefully abided by the editorial instructions and made all changes requested by Dr. Miller, the other reviewers, and the Editors.

> Reviewer \#1:
>
> The manuscript, \"Dual airway and alveolar contributions to adult lung homeostasis and carcinogenesis\" by Spella et al., employ specific cell labeling and transcriptomics to identify airway cell types in developing versus wounded versus carcinogen-induced adenocarcinoma induction. Overall, they find that \'airway cells\' are required for alveolar maintenance and lung carcinoma development. While the results documented in this manuscript could be compelling and many of the questions that they are asking are fundamental questions in biology and cancer, the written paper and figures were so hard to read that I cannot interpret them. There are no clues to all the acronyms and markers the authors use throughout the paper until potentially the summary at the last figure. It is not the job of the reader to do all the background reading to try to understand what the authors may or may not be trying to say. Therefore, while their findings may be compelling, the authors must find a way to relay a coherent story that is understandable to the wide audience at eLife.

We thank reviewer \#1 for the constructive criticism. In this revised form of the paper we tried to make the manuscript more coherent and the figures more comprehensible. Furthermore, we added tables listing and explaining the protein markers that we used in our studies.

> Additionally, I have a few comments, based on what I think I may have interpreted correctly.
>
> 1\) Is it really interesting to find that, \"Collectively, these results indicate that airway cells and/or transcriptomic signatures are essential for alveolar maintenance and LUAD development.\"? Are cells not within the airway expected to contribute to airway development and cancer. Again, this may lie within code words used between people in the lab that they haven\'t explained to other people. To me, airway cells include all cells within the airway, including stroma.

We thank the reviewer for this comment, which we tried to clarify in the revised manuscript. The novel concept we are proposing is that airway (or airway-reprogrammed) cells cause cancer in the alveoli, which is opposed to the doctrine that alveolar cells cause cancer in the alveoli (adenocarcinomas). Lungs are grossly comprised by two distinct compartments, the airways or bronchi and the alveolar parenchyma, and their homeostasis has been a longstanding issue in lung biology. A number of pulmonary lineage tracing studies utilizing noxious insults showed that each compartment is supposedly maintaining itself, with airway epithelial cells (AEC) sustaining the airways and alveolar type II (ATII) cells reforming the alveolar parenchyma. In lung adenocarcinoma, studies using genetic mouse models of oncogenic KRAS expression in the respiratory epithelium incriminated different cells as progenitors of lung adenocarcinoma, but these models are marginally human-relevant and their results rest on where the transgene is turned on.

> 2\) I think that the findings that carcinogenesis could come from faulty repopulation of adult cells following the continuous wounding of airway epithelia to be the most interesting finding of this study, yet it is not tackled directly. Is this something that the authors are saying?

Like reviewer \#1 so astutely deduces, we believe that airway epithelial cells significantly contribute to adenocarcinoma formation, as they are the first cells to be mutated after carcinogenic insults and this can of course affect the correct repopulation of the adult lung. We hope that in the revised version of our manuscript the interpretation of our findings will be clearer.

> 3\) The main problem with the paper is that the authors are using drivers of cell lines that they never describe or confirm with markers that are clearly labeled and cited. The reader has no idea what cells they are labeling with what driver and how we know that the labels are acceptable. Without this, the whole study could be a house of cards with interpretations depending on whatever they have decided to call cells.

We thank reviewer \#1 for the constructive criticism. In this revised version of the paper, we describe our mouse models more explicitly. Furthermore, we have added tables listing and explaining the protein markers that we used.

> 4\) They need to find a way to write in a way that captures the reader\'s attention so that we understand right upfront what the problem is that they are trying to address and how they will approach it. They could put the drivers and markers into a table, once they show clear evidence what cell type they refer to. Then refer only to the cell type in plain English, not a thousand acronyms.

We thank reviewer \#1 for the constructive criticism. According to his/her suggestions, we included tables listing the drivers and protein markers that we used. We have simplified our figures to clearly show the relation of each protein marker to the respective cell type. We now refer to our reporters as "GFP;REPORTER.CRE" in order to show which cell type is GFP labeled.

> 5\) There seems to be a very fuzzy plot throughout. They are using cell lines, ablation of certain cells, Cre-labeled cells and then they come up with very fuzzy conclusions. They might do well to reduce what they are looking at and come up with clear questions to the answers that they think that the experiments answer.

We thank reviewer \#1 for the constructive criticism. We hope that the revised form of our manuscript will be more comprehensible.

> Reviewer \#2:
>
> \[...\] Overall the paper is very interesting and loaded with information. The premise of the work is very strong. \"ablation of airway cells distorted alveolar structure and function and protected mice from LUAD development.\"
>
> The authors should be commended for the novelty of the work and for the potentially transformative findings bringing the plasticity of the conducting airway epithelial cells to the forefront of lung homeostasis and tumorigenesis. The paper does nail down in mice what specific cell type(s) in the conducting airway is at stake.

We thank reviewer \#2 for his/her positive comments and the appreciation of our work.

> The findings support that airway cells and/or transcriptomic signatures are essential for alveolar maintenance and LUAD development. This statement may be true in the mouse models generated but the evidence that would suggest that is can be true in humans is insufficiently developed.

We thank reviewer \#2 for the constructive criticism. Admittedly, our human transcriptomic analysis is not as rigorous as the respective analysis in mice. However, we believe that this can be explained by the early nature of the human surgical specimens that we used compared to our murine cell lines that represent advanced metastatic tumor-initiating cells. We agree with the reviewer's comment and included the limitations of our human data in the revised Discussion section.

> \"The data indicate remarkable plasticity of adult lung epithelial cells and suggest a central role for airway cells and transcriptional signature (s)in lung regeneration and cancer\". It remains unclear as to whether these scgb1A1 cells are migrating to the alveolar space or rather expressing CCSP by regenerating alveolar cells. The question is not settled by the results of these experiments, yet it has huge implications. The data seem to further support the concept of trans-differentiation which is not addressed in the paper. Isolation and transcriptional profile at the single cell level may solve the question.

We thank reviewer \#2 for the constructive criticism and the effort to improve our manuscript. Admittedly, our data set up doesn't address the issues of CCSP+ cells migration to the alveolar space and trans-differentiation. Single cell transcriptional profiling is one of our future steps, but we could manage to perform such studies to date. We have included this limitation in the revised Discussion section and have clearly stated that we do not definitively address the migration versus CCSP expression by regenerating alveolar cells issue.

> Upon exposure to urethane the Scgb1a1.cre;Dta and lyz2 were equally protected from developing lung ADC? Why would Lyz2 cells be needed for tumorigenesis is not clear.

LYZ2-expressing cells in the lungs are alveolar macrophages, but also half of alveolar type II cells (Nature 2014, 507:190-194). LYZ2+ alveolar cells have been previously shown to play a major role in adenocarcinoma formation in studies using mouse models of genetic activation of *KRAS* in alveolar cells. This finding is corroborated in our studies, since we show that a portion of tumors are LYZ2-labeled and LYZ2-ablated mice have less tumors in response to urethane. However, we show that many lung tumors arise independent from LYZ2+ cells, and that LYZ2+ cells in the alveoli have genetic airway labeling. The data collectively support previous findings, but imply that airway cells can be at the base of LYZ2+ cells in the alveoli.

> The paper is not well written overall and was very challenging to read/ review. The paper is structured in such way that we discuss lung tumors than homeostasis and repair and back to lung ADC. It is quite difficult to follow. There are many grammatical errors and too many shortcuts for expressing new concepts. It would benefit from simplification and from focusing the report on the main findings.

We thank reviewer \#2 for the constructive criticism. We hope that the revised form of our manuscript will be more comprehensible.

> Reviewer \#3:
>
> \[...\] As I am not an expert in cell lineage tracing, there may be issues here which I have missed. I believe that the results provide strong support for the importance of airway epithelial cells, rather than alveolar type II cells, in the genesis of many lung adenocarcinomas. Why the KRAS mutation specifically caused by urethane is maintained in airway epithelial derived cells but is not in alveolar type II cells is fascinating. This is highly relevant to prevention and risk determination. I do not suggest any major additional work.

We sincerely thank reviewer \#3, Dr. York E. Miller, for these positive comments and the appraisal of our work. This is especially important for us to keep going, since this comment stems from a pioneer in the field.

\[Editors\' note: further revisions were requested prior to acceptance, as described below.\]

> The revised manuscript is much easier to read. My only remaining issue with the revised paper is that the Title and Abstract are still confusing. The Title: The conducting airway epithelium (again that doesn\'t seem very specific) fosters (what does foster mean? usually it means to adopt for a short time or to nurture. It is still a vague word -- do you mean it acts like a seed or a soil? This is not a very cogent Title and needs help). Additionally, the Abstract\'s last two sentences are a jumble. Why not break them up into different sentences so that each has a precise meaning. Finally, \'lucrative\'? Is that what is being learnt here? They could be lucrative cells? I think that this needs a good rewrite. My sense is that this is an important paper that should be published but it really deserves to be understood by its readers. Therefore, I have asked for a full copyedit and I think it would be good to make sure that you are stating everything you want to say, especially in the Title and the Abstract, which will get the most readership.

We hereby resubmit a revised version of the above-referenced manuscript. As requested, we completely rewrote the Title and Abstract, and made additional edits throughout the paper. We are extremely thankful to you both for the time spent in reviewing our paper and for your positive appraisal of the work.

We are now clearly saying what we mean and hope the manuscript to be acceptable.

[^1]: These authors contributed equally to this work.
